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INTEGRIN α5β1 AS A NOVEL TARGET WITH THE SMALL PEPTIDE,  
ATN-161, IN THE TREATMENT OF ISCHEMIC STROKE 
 
Stroke is the 5th leading cause of death and the leading cause of disability 
in the United States, but there are only two available therapies, tissue plasminogen 
activator and endovascular thrombectomy. As both therapies focus on removal of 
the clot, the subsequent pathologic processes, i.e. inflammation, cerebrovascular 
breakdown, ATP depletion, etc. are left untreated, contributing to worsened patient 
outcome. Many clinical trials have unsuccessfully attempted to address these 
mechanisms. The blood-brain barrier (BBB), a system of non-fenestrated 
endothelial cells, extracellular matrix, and astrocytic endfeet, is significantly 
impacted after ischemic stroke in its role of preventing the free movement of 
proteins from the blood into the brain. In fact, BBB dysfunction is viewed as one of 
the major facilitators of damage following ischemic stroke, leading to increased 
infarct volumes and worsened patient outcomes. Interestingly, a family of 
endothelial integrins, the b1 integrins, have been shown to regulate tight junction 
proteins preventing the free movement of molecules. When expression of the tight 
junctions are decreased, this results in increased BBB permeability. To test this 
concept, our laboratory has previously shown the knockout of the particular b1 
integrin, a5b1, is neuroprotective following ischemic stroke through BBB 
stabilization.  
To determine if therapeutically targeting integrin α5β1 was feasible, we first 
determined if brain integrin a5b1 expression increases after experimental mouse 
ischemic stroke model, specifically tandem/transient common carotid artery/middle 
cerebral artery occlusion. We found that integrin α5β1	does increase acutely, by 
post-stroke day (PSD)2, and continued in an exponential fashion through PSD4. 
Next, we determined if integrin α5β1	was therapeutically accessible by systemic 
treatment (i.e. intraperitoneal or intravenous) by being located on the inside 
(luminal surface) of vasculature. We found that location of integrin a5b1 was 
dependent on the area relative to the stroke injury. The core, or area of direct 
impact, demonstrated expression of integrin α5β1	on the outside vasculature 
(abluminal surface), while per-infarct expression was localized to the lumen. Lastly, 
to determine the activity of integrin α5β1	following ischemic stroke, we showed that 
the potential ligands (binding partners), plasma fibronectin, fibrinogen, and 
amyloid-b, do not bind integrin α5β1	after ischemic stroke.  
Next, we determined the therapeutic potential of targeting integrin α5β1	with 
the small peptide, ATN-161. ATN-161 has undergone clinical trials in solid tumors, 
with limited side effects reported. First, we determined that intraperitoneal (IP) 
injection of ATN-161 was safe after ischemic stroke, showing no changes in heart 
rate, pulse distention (blood pressure), or body temperature. Next, we found that 
IP administration of ATN-161 after experimental ischemic stroke reduced infarct 
volumes, edema, and functional deficit. Furthermore, these results were due to 
reduction of BBB permeability and anti-inflammatory effects. Interestingly, ATN-
161 reduced cytokine production, prevented leukocyte infiltration, and leukocyte 
recruitment. Collectively, these results suggest that targeting integrin α5β1	with 
ATN-161 is 1) feasible, 2) safe and 3) effective, suggesting that ATN-161 may be 
a novel therapeutic treatment for ischemic stroke. 
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Chapter 1: Roles of blood-brain barrier integrins and extracellular matrix in 
stroke 
Danielle Edwards, and Gregory J. Bix 
 
Introduction 
Stroke is the fifth most common cause of death in the United States (separate from 
cardiovascular disease), with a person experiencing a stroke every 40 seconds (1). 
The most common type of stroke, ischemic stroke, is defined as obstruction of 
blood flow to part of the brain due to a thrombus or blood clot, and results in a one 
year patient survival rate of 60% (1-4). While all are potentially at risk for having a 
stroke, factors such as being male (or a post-menopausal female), African-
American, being of advanced age, and the presence of hypertension all increase 
a person’s risk of experiencing a stroke in their lifetime (5-11). Additionally, 
functional deficits induced by ischemic stroke are the leading cause of disability in 
the US and cause a $36-65 billion economic burden that is expected to increase 
to $180 billion by 2030 (8). Taken together, ischemic stroke is a significant health 
issue with limited therapeutic options. The current therapies, exogenously 
administered clot-busting tissue plasminogen activator (t-PA) and endovascular 
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mechanical thrombectomy (clot removal), are efficient in removing the thrombus, 
thereby increasing reperfusion rates by 60%, and decreasing mortality (since 
2013) (3-4). However, increased efficacy (i.e. morbidity) due to therapeutic input 
have largely lagged behind these gains in mortality (12-13).  
 
A proposed hypothesis to explain the lack of correlation between improved 
mortality rates and patient outcomes involves the mechanisms following 
reperfusion, so-called reperfusion induced injury. When reperfusion injury occurs, 
it often expands the initial brain injury caused by the occlusion (referred to as the 
core) to at risk brain tissue (referred to as the penumbra or peri-infarct region (14-
16). This occurs, in part, as the result of cerebral edema (brain swelling). The first 
phase of edema occurring at 0-24 hours post-injury is cytotoxic (ionic and 
metabolic dysfunction (16)) in nature, followed by vasogenic edema attributed to 
angiogenesis (new blood vessel growth) and reassembly of endothelial cell tight 
junctions (16-18).  
 
Edema greatly contributes to breakdown of the blood-brain barrier (BBB), a three-
layer defense system around the cerebral vasculature, preventing unwanted 
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molecules from entering the brain parenchyma. The BBB is comprised of non-
fenestrated endothelial cells with intercellular tight junctions and various influx and 
efflux cellular transporters, extracellular matrix (ECM) and its cellular integrin 
receptors, pericytes, and astrocytic endfeet (Figure 1.1) (16). BBB dysfunction in 
transient ischemic stroke models, in which a cerebral blood vessel is closed for a 
predetermined period of time and then reopened, occurs in two phases (biphasic 
permeabilization); at 30 minutes post-reopening of the blood vessel, and then 
again at 2-5 days post occlusion, lasting for up to 5 weeks (19-22). The loss of 
organization leading to BBB dysfunction can be observed by the loss of sharp 
distinction in the basement membrane 12-24 hours after ischemia, as shown by 
transmission electron microscopy (23). The importance of BBB dysfunction has 
come under high scrutiny over recent years, as studies have shown that BBB 
dysfunction can predict the probability of having an ischemic stroke as well as its 
outcome (24-28). This review focuses on the modulation of integrins and ECM 
components (existing in and around all cell types in the cerebrum) following 
reperfusion, and how this can lead to BBB dysfunction following ischemic stroke 
(Figure 1.2).  
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Figure 1.1: Representation of the blood-brain barrier during normal conditions.  
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Figure 1.2: Representation of integrin and extracellular matrix effects of the cerebral 
neurovascular unit A. during maturity and B. following reperfusion after ischemic stroke.  
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Proteins of the Blood-Brain Barrier 
Integrins 
Integrins as a whole are located on every cell type in the body. They are 
heterodimeric transmembrane proteins composed of non-covalently bound α and 
β subunits forming 24 known combinations (29). The different subunits have 
varying roles; the α subunit is responsible for intracellular signaling (30-32). 
Integrins exist in three states- active, at rest, and inactive, represented by different 
conformations (16,33). The conformational states differentially expose the binding 
domain, typically Arginine-Glycine-Aspartate (the three-amino acid sequence, 
RGD) and determine the relative (none, intermediate, or high) affinity an integrin 
will have for ECM components (16,34). Once bound to their corresponding ECM 
protein, the integrin-ECM complex functions to promote cellular signaling, 
proliferation, migration, differentiation, and survival (35-38). We will first discuss 
several key integrins that have been implicated in BBB function after stroke, and, 
where known, their respective therapeutic target potential. Here, we will discuss 
integrins associated with the extracellular matrix, though blood borne integrins 
(α2β1 and α11bβ3) are also effected following ischemic stroke. 
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Integrin αvβ3  
Embryonically, integrin αvβ3 is highly expressed on endothelial cells, astrocytes, 
and microglia, binding to a number of ECM components including fibronectin, 
vitronectin, osteopontin, laminin, etc. (39-42). Functionally, αvβ3 is essential to 
angiogenesis, as 80% of αv knockout mice are embryonic lethal by E10-12 with 
placental and heart defects, though this is not completely attributed to the β3 
subunit as αv can also associate with β3, β5, β6, and β8 subunits with varying 
viability (43). The remaining 20% of mutants survive through gestation, but end up 
succumbing to intestinal and cerebral hemorrhages at birth (43). Interestingly, 
conditional αv knockout mice also result in non-survivability due to intracerebral 
hemorrhages, but not by loss of integrin αv on endothelial cells. Instead, integrin 
αv absence on glial cells and astrocytes facilitates detachment of astrocytes from 
the ECM, an increase in permeability of the BBB, and intracerebral hemorrhage 
(44). Completion of development results in total loss of αvβ3 expression under 
physiologic conditions (41).  
 
After experimental ischemic stroke (middle cerebral artery occlusion (MCAO)) in 
adult rodents, expression of integrin αvβ3 is significantly increased by 2 hours in 
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the ischemic core and continues to increase in the ischemic penumbra until 
expression peaks at 7 days post stroke (45-46).  This correlates with increases in 
the ECM proteins fibronectin and vitronectin as well as increasing vascular density 
(as determined through brain endothelial proliferation) through post stroke day 14 
in the ischemic penumbra (45-46). Furthermore, vascular endothelial growth factor 
(VEGF) (47), a known inducer of integrin αvβ3 expression, activity, and ligand 
affinity, has a similar pattern of upregulation after MCAO, increasing around 1 hour 
post-reperfusion and remaining for up to 7 days (45,48). The increase in αvβ3 post-
stroke induces occludin and zona occludins (ZO-1) (tight junctions of brain 
endothelial cells) internalization, disrupts VE-cadherin localization (a tight junction 
regulating protein), induces stress fiber formation, and increases expression of 
ECM degradation proteins, matrix metalloproteinase (MMP) -2 and -9 (27,41,49-
54). These outcomes initiate angiogenesis, a process that was previously thought 
to be beneficial by increasing blood supply to a previously hypoperfused area, but 
is now known as a main contributor to the chronic (2-5 day) increase in BBB 
permeability after reperfusion (16).  As αvβ3 is a known promoter of the chronic 
(2-5 days) increase in permeability observed after reperfusion, it may be a good 
target for ischemic stroke intervention (16).  
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Over the last few years, different modes of targeting integrin αvβ3 therapeutically 
have been attempted with contrasting results. The first and most promising 
combined a 1 hour pre-MCAO and 3 hours post-MCAO therapeutic treatment with 
an integrin αvβ3 selective inhibitor, cyclo-RGDfV, which showed reduced infarct 
volumes and BBB permeability (55). However, prophylactic treatment for ischemic 
stroke is not a viable clinical option as we cannot predict the moment a stroke will 
occur. Because of this, the same group attempted to inhibit αvβ3 3 hours post-
MCAO. A decrease in BBB permeability was still observed, but the resulting 
decrease in infarct volume was not significant in this dosing paradigm (56). 
Additional results with the cyclo-RGDfV inhibitor demonstrated a decrease in 
phosphorylated Flk-1, a specific vascular endothelial growth factor (VEGF) 
receptor, that when phosphorylated, increases VEGFa production, consistent in 
both dosing windows (55-56). This suggest that the decreases in BBB permeability 
are due to changes in VEGF- αvβ3 mediated angiogenesis, but inhibition of this 
mechanism alone in insufficient to modulate infarct volumes. This may be due to 
inhibitor dosing schedule (first dose is too late or repetitive dosing is necessary) or 
that additional mechanisms are required for effects on infarct volume.  
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Integrin α5β1  
Integrin α5β1’s main function is to promote embryonic angiogenesis, but it has also 
been implicated in cell migration, cell adhesion, and cell survival (57). It is also 
present on many different cell types, most notably on endothelial cells and 
astrocytes in the cerebrum, with a preference for interacting with the ECM proteins 
fibronectin, laminin 10, and osteopontin (57). Even with its diverse binding 
preferences, integrin α5β1 is primarily known as a fibronectin receptor (57). 
Interestingly, recent research has shown that integrin αvβ3 competitively binds to 
fibronectin, creating cross-talk signals that recruit integrin α5β1 at an opposite, 
unspecified site on fibronectin (58). Ultimately, these interactions increase the 
adhesion of both integrins αvβ3 and α5β1 to fibronectin (58). Unlike with integrin 
αvβ3’s non-detectable expression in adult microvasculature, after embryogenesis, 
integrin α5β1’s expression decreases but is still present at low levels in adult 
vasculature (41,46,57). The relevance of integrin’s α5β1 in development is 
apparent, as multiple α5 knockout mice models do not survive past E11 due to 
neural tube defects, lack of angiogenesis, and leaky blood vessels (43,59-61).  
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α5β1 may play a key role in many different diseases. Notably, targeting α5β1 in 
cancer has been highly studied as it is significantly upregulated in tumorgenesis, 
with functions in tumor development, angiogenesis, and progression (57). This 
increase is not limited to cancer, but is observed in models of experimental 
ischemic stroke, increasing in the ischemic penumbra around day 4 until peak 
expression at 7 days post-stroke, the same pattern of expression as αvβ3 integrin 
and brain endothelial cell proliferation (46). Unlike with αvβ3, there is a 
compensatory increase in integrin α5β1 when integrin αvβ3 is inhibited (62). 
Furthermore, α5β1 is closely linked to VEGF receptor-1 (VEGFR-1) (as seen by a 
solid-phase binding assay), and upon cross-talk, enhances cell migration, 
proliferation, and adhesion, processes which are blocked upon use of integrin α5- 
antibodies and knockout mice (63-64). Because of its strong angiogenic ties, 
integrin α5β1 has been highly targeted as a means for therapeutic intervention in 
inhibiting angiogenesis for many decades with varying results (refer to ref 9 for 
further information), but its role in angiogenesis and stroke pathology has been 
largely ignored until recently. 
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Roberts et al studied the effects of integrin α5β1 in endothelial specific knockout 
mice after MCAO with surprising results (65). These mice, unlike the previously 
discussed pan knockouts, are not embryonically lethal and have no obvious 
vascular or developmental changes (65-66). Surprisingly, these knockout mice 
suffered significantly smaller infarcts compared to their wild type controls through 
apparent stabilization of the BBB as shown by an absence of IgG (150 kDa) 
extravasation into the brain parenchyma (65). This is suited toward the hypothesis 
that inhibition of angiogenesis, in this case through inhibition of integrin α5β1, 
prevents a remodeling of neurovasculature initiated by vasogenic edema. As 
embryonic pan-deletion of integrin α5 contributes to abnormal angiogenesis and 
leaky blood vessels (59-61), inhibition of integrin α5β1 therapeutically in already 
developed, adult vasculature could be an avenue for future ischemic stroke 
intervention.  
 
Integrin α6β4  
Integrin α6β4 is mainly expressed on astrocytes, but also on endothelial cells, 
though it is not expressed during embryogenesis, but rather during adult 
vasculogenesis due to the switch from fibronectin- to laminin-driven angiogenesis 
  14 
(66-68). Initially, α6β4 decreases within 2-4 hours after MCAO, but begins to 
increase at day 4 and continues to peak expression by day 14 (66-69). Increased 
α6β4 expression also correlates to increasing brain endothelial cell proliferation 
(reaching its peak at day 7), which swaps with astrocytic proliferation that peaks at 
day 14 (46,64). The astrocytic effects after ischemic stroke will be discussed later 
in this review.  
 
Integrin α6β1  
As with most β1 integrins, α6β1 integrin is expressed on endothelial cells in the 
brain (39). During embryogenesis, the endothelial integrins α5β1 and αvβ3 are the 
most highly expressed, but an integrin switch occurs for the laminin binding α6β1 
integrin in adulthood (67).  α6β1 continues to be the dominantly expressed β1 
integrin in mature vessels, but this is quickly switched for α5β1 after cerebral 
hypoxia, once angiogenesis is initiated (62). Current research on therapeutically 
targeting this integrin has focused on blocking it to prevent angiogenesis in solid 
tumors with very limited study in ischemic stroke.  
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Integrin α1β1  
α1β1 integrin is present on endothelial cells and astrocytes, preferably binding to 
the ECM components collagen IV and perlecan. Embryonically, α1 integrin subunit 
knockout mice show no lethality and finite defects, limited to cell proliferation 
complications (43). On the contrary, β1 integrin subunit knockout mice, eliminating 
all the various integrins with a β1 component, show neonatal lethality at E6 while 
embryonic stem cells without β1 integrin result in hematopoietic defects (43). After 
experimental ischemic stroke, α1β1 expression (by probing α1 and β1 separately) 
decreases by 30% within 2 hours, and 75% by 24 hours after occlusion (69). 
Further studies with integrin β1 inhibitory antibodies have resulted in severe 
deficiencies in BBB stability as well as promoting a decrease in expression of the 
tight junction protein claudin-5 and shifting its localization away from the 
extracellular wall, suggesting a significant role in BBB maintenance embryonically 
and at maturity (70), though no further research has been conducted in this regard 
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Integrins: Conclusion 
As described here, the variety of integrins in the brain is expansive in terms of type, 
function / preferred ligand(s), and expression. The highly reactive nature of 
integrins suggests a new approach for potential ischemic stroke therapy, as 
evidenced by a relatively recent increase in the number of studies focused on them. 
However, the success of modulating these integrins to therapeutic effect is thus 
far as varied as is the integrins themselves.  
 
Extracellular Matrix Proteins 
Collectively, the ECM consists of multimeric proteins that participate in cellular 
migration and differentiation as well as functioning as a support system for 
endothelial cells and astrocytes when in complex with integrins, and is composed 
of a combination of proteoglycans, glycoproteins, and collagens (71-72). The ECM 
is vital for development, function, and regulation of vasculature, tight junctions, 
neurons, and astrocytes through cellular signaling and adhesion (73). Defects in 
any ECM protein can result in serious developmental and functional complications 
(73). Here, we will discuss the cerebrovascular extracellular matrix proteins that 
interact with integrins following ischemic stroke. 
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Fibronectin 
The ECM glycoprotein fibronectin is a disulfide-linked dimer (~250 kDa per 
monomer) that can exist as a soluble form, plasma fibronectin produced by 
hepatocytes in the liver, or insoluble form, cellular fibronectin produced by 
fibroblasts in the basement membrane (66,74-76). Developmentally, fibronectin is 
significantly increased in the basement membrane, driving angiogenesis in 
developing vasculature through binding to integrins α5β1 and αvβ3 (77-78). 
Fibronectin knockout mice are embryonic lethal at E10 due to severe vascular, 
notochord, and somite deformities, due to genetic manipulation to the fibronectin 
gene before isoform formation due to splicing can occur (59). This is evident as 
the cellular fibronectin isoform is necessary for cerebral vascular development, but 
these vasculature and notochord deformities, in addition to preventing lethality 
from the null gene, are prevented in the plasma fibronectin null mouse (66,79-80).  
 
Fibronectin is highly reactive after stroke, increasing in the ischemic penumbra 
until peak expression at 7 days post MCAO, but the researchers did not separate 
expression by isoform (46,81). Previous studies suggest that the increase is due 
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to trafficked plasma fibronectin to the infarct area 2 days post MCAO (79). To 
further reinforce this concept, plasma fibronectin null mice that underwent MCAO 
had significantly increased infarct volumes and increased TUNEL (apoptotic cells) 
staining compared to their wild-type controls with no compensation from cellular 
fibronectin (79,82).  
 
Not only is fibronectin responsive after stroke, but it is also vulnerable to 
degradation from proteases, most notably MMPs (83-84). MMP-9 is increased by 
48 hours after ischemic stroke in humans (85), but also after intracerebral 
hemorrhage induced by VEGF injections and IL-1β induced systemic inflammation 
by nearly 6-fold (86-87), increasing the degradation of ECM proteins. With this 
relationship in mind, serum levels of cellular fibronectin and MMP-9 are increased 
in patients who experience a hemorrhagic transformation following ischemic stroke 
(88-89). Interestingly, the higher levels of both cellular fibronectin and MMP-9 
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Laminin 
Laminin is a heterotrimeric protein composed of different α, β, and γ subunits to 
form 15 different isoforms (90-93) that exists in endothelial cells and astrocytes. 
While embryonic angiogenesis is driven by fibronectin, this is substituted by 
laminin during adult angiogenesis (67,94), though this process will continually 
alternate during VEGF stimulated injury (i.e. tumor growth and metastasis, 
ischemia, wound healing, etc.) (31,46,67,81). Of the 5 α, 4 β, and 3 γ laminin 
subunits, laminin 8 (α4β1γ1) and 10 (α5β1γ1) are endothelial specific, while 
laminin 1 (α1β1γ1) and 2 (α2β1γ1) are expressed solely on astrocytes (95-98). It 
is important to note that only laminin 8 is expressed during development, while the 
first detectable levels of laminin 10 are 3-4 weeks post-birth in mice (91,99). The 
importance of laminin to vascular integrity is obvious as laminin α4 knockout mice 
and laminin γ1 knockout mice suffer from leaky vasculature and experience 
intracerebral hemorrhages, leading to lethality at E6 (99-100). Further study with 
conditional laminin α4 knockout mice show similar defects in vasculature that again 
lead to intracerebral hemorrhages (101-102). 
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Laminin’s main role after ischemic stroke appears to be more aligned with its 
endothelial cell interactions. Within 24 hours after MCAO, increases in laminin in 
both endothelial cells (laminin 8 and 10) and astrocytes (laminin 1 and 2) in the 
ischemic penumbra are observed (95,103). Alternatively, there is a decrease in 
endothelial laminin located in the ischemic core due to loss of vasculature from 
ischemic conditions (81). Endothelial laminin, specifically laminin 10, is also 
essential for BBB integrity after in vitro oxygen glucose deprivation by regulating 
occludin and ZO-1 expression and localization to the extracellular cell wall, 
decreasing paracellular resistance through the endothelial cells (104). Finally, 
activation of integrin α2β1 by its binding to endothelial laminin halts endothelial 
proliferation (105), a process that is slowed around 7 days post MCAO (59) when 
astrocytic proliferation takes over (46,67).  
 
Chronic repair has been implicated in laminin-initiated mechanisms driving 
neurogenesis after MCAO. Endothelial laminin promotes neurite growth in vitro 
(106), but has yet to be detected in in vivo studies.  Recent studies have shown 
laminin in conjunction with β1 integrin in providing scaffolds, a neural chain that 
promotes neuronal migration toward injury, 16 days after occlusion (107). Although 
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laminin-mediated neurogenesis after MCAO is poorly understood, the impact that 
this glycoprotein has on neurogenesis could be significant. 
 
Perlecan 
Perlecan is a heparan sulfate proteoglycan that contains a protein core with 5 
different domains (domain I-V) and three glycosaminoglycan chains at the N-
terminus and is most commonly found in hyaline cartilage, but is also located in 
basement membranes throughout the body (108-110). Overall, perlecan plays a 
major role in cellular migration, proliferation, and differentiation, but the individual 
domains have functions and binding domains unique to their sequence and 
structure (6,110). Perlecan, like fibronectin and laminin, is upregulated during 
embryogenesis around cerebral vasculature to provide maintenance and 
assemble the developing basement membranes (47,111). When absent from the 
basement membrane, complete perlecan knockout mice result in embryonic 
lethality at E12 resulting from cardiac failure and exencephaly, with surviving 
embryos soon succumbing to their skeletal, cardiac, and cerebral defects 
(47,111,112). On the other hand, a second type of transgenic mouse with 
truncated perlecan (producing 10% of total perlecan, perlecan hypomorphs) yield 
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surviving neonates that have a normal basement membrane, but are still 
susceptible to exencephaly as well as exhibit truncated skeletal features (47,113). 
Collectively, the loss of perlecan embryonically and in maturation display 
significance in both transgenic mouse models show high importance in basement 
membrane maintenance in both development and adulthood, and though perlecan 
is mostly known for its functions in hyaline cartilage, it has shown interesting 
promise as a target for ischemic stroke therapy (108,93). 
 
Perlecan is decreased by 43-63% within 2 hours of reperfusion after MCAO and is 
continually degraded through day 7 by cathepsin (caspase) B and L (62,114). 
Cleavage by cathepsin L on perlecan releases the C-terminal fragment domain v 
within hours after experimental ischemic stroke, resulting in a strong increase by 
24 hours post-reperfusion that is sustained through 7 days (115). Treatment with 
exogenous recombinant domain V after MCAO not only is neuroprotective in wild-
type mice, but rescues pathology in perlecan deficient mice (i.e. perlecan 
hypomorphs), thus reducing infarct volumes and improving functional outcomes 
(neuroprotection and neurorepair) (114-116). Furthermore, the neuroprotective 
effects of domain V were blocked upon administration of an anti-α5β1 antibody. 
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Interestingly, integrin α5β1 is a potential receptor of domain V, but not perlecan 
(115). Collectively, these results suggest that perlecan, and its domain V in 
particular, play a fundamental role in the brain’s response to ischemic stroke injury. 
 
Collagen IV 
Collagens are an abundant basal lamina protein expressed on all tissue types in 
the body (117). Of the variety of collagens, the most abundant in the basement 
membrane in the body is collagen IV, a nonfibrillary collagen (117). Even though 
collagen IV is one of the three main components of the basement membrane 
(laminin and heparan sulfate proteoglycans composing the rest), embryonically 
knocked out collagen IV result in no cerebral deficits, but rather only appearing to 
affect renal development (43,117). Interestingly, mature mutations can result in 
ischemic strokes in young patients, potentially resulting in a significant role in post-
stroke pathology (118). Studies in collagen IV expression have been contradictory. 
One study using western blot analysis shows a reduction in collagen IV after 
experimental ischemic stroke that corresponds to a decrease in cerebral 
vasculature (119). Although, more recent studies have observed the opposite 
phenomenon when analyzing by immunohistochemistry (120). Here, the authors 
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themselves admit the potential false-positive in the results because of a potential 
increase in degradation (i.e. more proteins available for targeting) or as a result of 
the neurovasculature over compensating to stabilize damaged vessels (120). 
These conflicting results need more investigation and improvement before any 
determination of collagen IV’s impact on stroke severity or post-stroke recovery 
can be made. 
 
Extracellular Matrix Proteins: Conclusion 
The proteins in the extracellular matrix surrounding endothelial cells and astrocytes 
are primarily composed of collagen IV, laminin, heparan sulfate proteoglycans, and 
fibronectin. This diverse group has a variety of reactions following stroke, but 
overall are attributed to the BBB stability, an important target to reduce the 
expansion of damage and edema. The interest in targeting these proteins has 
been limited at best, most likely due to a decrease in accessibility on the basal side 
of the endothelium. Current focus is on modulating these proteins through other 
mechanisms, such as reducing MMPs, targeting integrins, and understanding the 
full reactive mechanisms after ischemic stroke.  
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Cellular Components of the BBB 
As discussed, integrins and ECM proteins are not limited to endothelial cells, but 
span all cell types in the neurovascular unit including astrocytes and pericytes. 
When ischemia and the following inflammatory, vasogenic, etc. mechanisms 
influence these BBB components, it can directly affect BBB permeability (16). 
Below, we briefly describe the rest of the cells that comprise the BBB with a 
particular focus on how their interactions with the ECM via integrins affect the BBB 
after ischemic stroke.  
 
Endothelial Cells 
Endothelial cells are responsible for the first layer of the BBB, providing a scaffold 
for TJ,  junctional adhesion molecules (JAM), and the extracellular matrix (as 
discussed throughout this review). Heavy scrutiny has been placed on paracellular 
permeability, permeability between endothelial cells, as the main regulator for post-
stroke edema (121). Until recently, little importance has been placed on 
transcellular permeability, permeability through an endothelial cell. It has now been 
shown that endothelial cells undergo a 4-step process after ischemic stroke, 
localized to the core (122). First, endothelial cells swell, potentially attributed to 
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activation of connexin-43, a gap junction protein (121), Next, endothelial cells gain 
a permeable surface. Here, an increase in transcytotic, particularly caveolin-1, and 
pincytotic vesicles begin to compromise the endothelial cells and cause an 
increase in BBB permeability at 4-6 hours (121-124).  Interestingly, at this time, 
there appears to be limited compromise of the tight junctions. This process leads 
to free movement of molecules across the endothelial cell, eventually resulting in 
a loss of endothelial integrity (121). Finally, this is followed by a loss of endothelial 
integrity, Once the extracellular matrix is exposed, endothelial cell loss occurs 
(124). The endothelial role in BBB permeability is shown to be resolved 24 hours 
post-stroke (122). Because of this process, the early damage done to endothelial 
cells following ischemic stroke could be a potential therapeutic target of acute 
treatment.   
 
Astrocytes 
Astrocytes, particularly their extended endfeet surrounding the ECM and pericytes, 
are the last line of defense to prevent unwanted proteins, molecules, etc. (125). 
The endfeet are also stabilizers of the BBB by releasing paracrine signaling (as 
determined by neurons), but can modulate cerebral blood flow, neuronal functions, 
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and tight junction formations as well (126-130). Astrocytic dysfunction, as seen by 
the separation of astrocytic endfeet with the basement membrane, occurs early 
after MCAO, within 2 hours (53,59). This process is referred to as astrocytic 
swelling and corresponds to increases in BBB permeability by way of cytotoxic 
edema, the loss of two astrocytic-endothelial cell anchoring proteins, α1β1 and 
α6β1 integrins, and an increase in excretion of MMPs (69,86-87). Overall, this 
acute mechanism after ischemia is responsible for cellular death of astrocytes, 
exacerbating cytotoxic edema and BBB dysfunction and thus the damage after 
ischemic stroke (69,82,131).  
 
Interestingly, expression of the astrocytic-associated integrins has been the focus 
of post-stroke research, but little attention has been placed on their potential as a 
therapeutic target (see above).  A possible explanation for this may be due to the 
loss of astrocytes inducing demyelination in the white matter that is absent in grey 
matter (132). Previous research has described a higher contact between the 
astrocytes and endothelium in the white matter (101). Because rodents possess 
significantly less white matter than humans, this increases the difficulty and 
potential lack of translation of any therapy targeting astrocytic associated integrins. 
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Pericytes 
Pericytes exist between astrocytes and the ECM to form a support system 
(scaffold) for endothelial cells as well as to send paracrine signals by direct contact 
to the endothelium (133-134). Additionally, pericytes are essential for regulation of 
ECM proteins, particularly astrocytic laminins 1 and 2 (135). After ischemia, 
pericyte detachment occurs within 2 hours post reperfusion, inducing 
hypoperfusion. Increases in post-stroke VEGF levels facilitate the detachment of 
pericytes from the endothelium, promoting an increase in MMP-9 expression 
(increasing ECM degradation) and caveolae-mediated transyctosis (increased 
BBB permeability) in both in vivo and in vitro models (5,136-141). Furthermore, 
these pericytic induced increases in BBB permeability is region specific, occurring 
more prominently in the cortex, striatum and hippocampus (142). Administration of 
a VEGF inhibitor in vitro reversed the BBB permeability effects (136). Pericytes are 
also composed of actin and myosin filaments, generating smooth muscle type 
actions (116,144). Contraction of the pericytes, decreasing the diameter of 
capillary vessels, is due to the acute ATP depletion following ischemic reperfusion, 
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resulting in a reduced or complete lack of cerebral blood flow even after removal 
of a thrombus (“no-reflow” phenomenon) (98,145-147).  
 
Future Considerations 
Integrins, ECM constituents, and the rest of the components of the BBB are 
significantly impacted after ischemic stroke. From the influence of integrin-ECM 
complexes, growth factors, TJ remodeling, MMPs, etc. there are many different 
targets that one could turn their attention to for potential breakthroughs in 
understanding stroke pathophysiology and developing new therapies, although 
some may have more promise than others (Figure 1.3).    
 
The importance of these components, particularly integrins and ECM proteins, in 
embryonic development convey their fundamental necessity for cerebral 
vasculature development and maintenance as demonstrated by embryonic 
lethality of nearly every knockout. Because of this, genetic changes (mutations, 
deletions, etc.) may influence the probability of experiencing a stroke and/or a 
stroke’s severity, whether from BBB dysfunction or clot formation (i.e. α2β1). For 
example, recent investigation has found that a polymorphism in the α2 subunit at  
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Figure 1.3: Proposed future applications for integrins and extracellular matrix in ischemic 
stroke. 
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C807T increases the probability of stroke by 1.266 times (148). This discovery is 
limited to clot formation, most likely due to increases in cholesterol in these patients 
(148), but the significance of potential genetic alterations should not be 
understated. 
 
As discussed, it is proposed that vasogenic edema after ischemic stroke is driven 
by angiogenesis (16-18) and the reorganization of BBB that must occur during this 
process. Angiogenesis after ischemic stroke is separated into three stages, 
initiation, migration and stabilization of new vasculature, and maturation (149-150). 
Previous studies that have focused on increasing angiogenesis after ischemic 
stroke based on the fact that patients with increased cerebrovasculature 
experience better outcomes, have had limited success (151-152). Instead, our 
focus may need to turn toward inhibiting pro-angiogenic integrins (α5β1 and αvβ3) 
and ECM proteins (fibronectin) to prevent early angiogenesis.  This appears 
counterintuitive; why prevent the growth of new blood vessels to an area that has 
experienced significant loss of cerebral blood flow and damaged vasculature in the 
ischemic core? As discussed in this review, mechanisms following ischemic stroke 
not only increase pro-angiogenic proteins, but also growth factors (VEGF) that in 
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turn facilitate the release of pericytes from vasculature, and MMPs, increasing BBB 
breakdown. Furthermore, the novel finding that α5 endothelial specific knockout 
mice have smaller infarcts and less BBB disruption after MCAO (65) reinforces the 
idea that early angiogenesis, by destabilizing the BBB, is detrimental to acute 
stroke injury and could be a therapeutic target in the future.  
Furthermore, because components of the BBB are highly reactive after ischemic 
stroke, novel imaging techniques could be used to visualize the ischemic core and 
penumbra days after the initial injury. Efforts in this direction have been made, 
specifically with gadolinium tagged αvβ3 in both ischemic stroke and myocardial 
infarction (Ga-PRGD2) under CT scans (153). Interestingly, researchers were able 
to detect αvβ3 differences between control patients and injury patients, up to 14 
years post-stroke, but significant differences were observable only up to 3 weeks 
post-stroke (124). Furthermore, the amount of αvβ3 correlated to the severity of 
the injury, thus the more severe the injury, the more αvβ3 was detectable by CT 
with Ga-PRGD2 (153). This technique is in early development, especially for stroke, 
as most significant differences were observed in patients who experienced a 
myocardial infarction (153), but this establishes precedent for targeting proteins 
that are upregulated after stroke.  
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Finally, biomarkers for stroke severity and/or BBB dysfunction are highly sought 
after as an inexpensive, quick diagnostic. As previously discussed, increased 
levels of cellular fibronectin and MMP-9 in the serum could predict hemorrhagic 
transformation and severity of bleeding in ischemic stroke patients. Additionally, 
the degraded portions of TJ proteins enter the lumen of the vasculature and can 
be analyzed in a time dependent manner. Specifically, levels of the TJ protein 
occludin increase in the serum by 4.5 hours after ischemic stroke and continue 20 
hours later (24 hours after ischemia) (154). Collectively, these potential serum 
biomarkers could predict the risk of hemorrhagic transformation after ischemic 




Taken together, ischemic stroke has a complex multifactorial and spatiotemporal 
impact on the BBB. Because of this, previous hopes that targeting any singular 
aspect of BBB stroke pathophysiology might produce a “magic bullet” for ischemic 
stroke treatment are unlikely to bear fruit. Instead, an effective therapeutic target(s) 
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is likely to require multifactorial mechanisms of action on the BBB and multiple 
treatments may need to be used in combination to affect such benefit. 
Consequently, interest in the BBB, integrins and the ECM, in the context of stroke, 
have never been higher, and will undoubtedly lead to novel discoveries and new 
stroke therapies in the not-to-distant future.   
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Chapter 2: Integrin a5b1 is acutely upregulated on abluminal vasculature in 
the core and luminal vasculature in the peri-infarct with unique ligand 
binding 
Danielle N Edwards, Justin F Fraser, and Gregory J Bix 
 
Introduction 
Integrins are heterodimeric transmembrane proteins consisting of 24 diverse a and 
b subunits (29). Each integrin combination has a different role in ligand/cell 
anchoring, cell signaling, cellular migration, etc. Additionally, the integrin 
heterodimers are broken into different ligand partners, such as RGD binding, 
laminin binding, and leukocytic integrins (29). Amongst this integrin diversity, one 
integrin in particular, a5b1, has shown to be of interest in multiple disease states 
including cancer, vascular disease and stroke (46,57,155,159). This is due to the 
main role of integrin a5b1, angiogenesis, but also due to its role in cell migration, 
cell signaling, and neural tube formation (29, 158). Though expression is highest 
during embryonic development, integrin a5b1 expression is reduced to low, 
sometimes undetectable levels in maturity until stimulated (57).   
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Because of its high impact in angiogenic disease, many cancer pre-clinical and 
clinical trials have targeted integrin a5b1 with monoclonal antibodies and the small 
peptide inhibitor, ATN-161 (57,156). Due to the increase in antibodies targeting 
integrin a5b1, Magnussen et al noticed that antibodies were quickly bound by 
accessible integrin a5b1 when intravenously injected (157). They determined that 
this may be due to the luminal expression of the integrin in pro-angiogenic tumors. 
This result is intriguing as the preferred ligand, fibronectin, is located in the 
extracellular matrix on the abluminal vasculature. Furthermore, integrin a5b1 has 
a unique synergy binding area, Pro-His-Ser-Arg-Asn (PHSRN). This synergy 
region increases integrin a5b1’s affinity (preference) and avidity (bonding strength) 
for fibronectin. 
 
Ultimately, we want to determine the therapeutic potential of targeting integrin 
a5b1 in stroke based on data our lab found in a5 knockout mice (65). To do this, 
we first aim to verify the increase in integrin a5b1 expression in our 
tandem/transient ipsilateral common carotid artery/middle cerebral artery 
(CCA/MCA) occlusion model. Next, we want to determine the vascular localization 
of integrin a5b1 and the potential ligand following experimental ischemic stroke.  
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Methods 
Animals 
All animal studies were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Kentucky prior to their performance.  
 
Stroke Surgery 
C57/Bl6 wild-type, male mice underwent transient tandem ipsilateral CCA/MCA 
occlusion for 60 minutes as previously published (158), followed by reperfusion for 
1-4 days. Briefly, a small burr hole is created directly over the M2 branch of the 
MCA, and a metal filament, diameter 0.0005 inch, is placed under the artery on 
both sides of the burr hole. The CCA was then isolated and occluded using an 
aneurysm clip. Blood flow was determined with the Laser Doppler Perfusion 
Monitor (Perimed, Ardmore, PA, USA). Animals that received less than 80% 
occlusion rate from baseline (i.e. pre-occlusion) were excluded from analysis. 
Sham animals underwent the listed procedure without vascular occlusion. All mice 
were allowed to recover to post stroke day (PSD) 3, during which daily body 
weights were measured.  
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Tissue Histology and Immunohistochemistry 
On PSD3, brains were removed, flash frozen in liquid nitrogen, and stored at -20C 
until use. The brains were sectioned by cryostat at 20µm and mounted on slides 
for staining. Sections were fixed in methanol:acetone (1:1), followed by blocking 
buffer (5% bovine serum albumin (Fisher Scientific) in PBS with 0.1% Triton-X). 
Sections were incubated in primary antibody overnight at 4C (anti-rat CD49e at 
1:250, BD Pharminagen; anti-rabbit collagen IV at 1:250, Abcam; anti-rabbit 
Fibronectin at 1:200, Abcam; anti-rabbit Fibrinogen at 1:200. Abcam; anti-rabbit 
amyloid b (1-40) at 1:100, Biolegend). Sections were washed and placed in 
fluorophore-conjugated secondary antibody at room temperature (Vector Labs, 
1:250). Sections were washed and incubated with NucBlue (Fisher Scientific), 
cover slipped (Vector Labs) and imaged on a Nikon Eclipse Ti (Nikon, Melville, NY, 
USA) or Nikon TI-E C2 Confocal (Nikon, Melville, NY, USA) and software. 
 
Statistical Analysis 
All pixel density data was placed at sham threshold for analysis. All measureable 
values are presented as mean ± SEM. Sample size was determined for 80% effect 
by power analysis. For multiple comparisons, a two-way repeated measures 
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ANOVA was used with the posthoc Bonferroni test. Significance is determined as 
p*<0.05, p**≤0.01, p***≤0.001, and p****≤0.0001. Outliers were determined by 
the interquartile range (IQR). 
 
Results 
Integrin a5b1 is upregulated following experimental ischemic stroke. 
Following intraluminal ischemic stroke models, infarct volumes are large with no 
peri-infarct area while being largely contained to the striatum. In these 
experimental conditions, integrin a5b1 expression is shown to noticeably increase 
at PSD4, peaks at PSD7, and returns to baseline expression at PSD14 (46,63). In 
contrast, our transient occlusion model produces small, cortically limited infarcts 
with peri-infarct territory. To determine the expression of integrin a5b1 in our model, 
we measured a5 positive pixels (green) on PSD1-4 and sham animals (Figure 2.1). 
Analysis showed increased integrin a5b1 expression at PSD2, though not 
significantly from sham. From there, integrin a5b1 expression continued to 
increase in an exponential way through PSD4 (Figure 1). PSD4 (10955±2340, 
n=4) expression was statistically significant upon analysis with one-way ANOVA 
  40 
compared to Sham (360±0, n=2; p=0.0089), PSD1 (487.7±105.6, n=3; p=0.0045), 
PSD2 (1245±389.3, n=3; 4218±1714, n=4; p=0.0076), and PSD3 (p=0.0452). 
 
Integrin a5b1 is expressed in a location depended manner  
Previous studies showed luminally expressed integrin a5b1 on the luminal (apical) 
vasculature in tumors (157). To determine the vascular expression, we first 
analyzed integrin a5b1 (green) endothelial expression based on arrangement 
around the extracellular matrix protein, collagen IV (red), in both the core and peri-
infarct of perfused animals. The core is the area of initial injury, while the 
surrounding peri-infarct region is at risk tissue that has not yet been injured from 
the ischemia. In the core, green a5 pixels are seen mostly in association with the 
abluminal vasculature, while little remains inside the vasculature integrin a5b1 and 
collagen IV co-stain (Figure 2.2A). We then used confocal microscopy to create 
models of the vasculature (Figure 2.2B) where we confirmed the abluminally 
expressed integrin a5b1.  
 
In contrast to core vessels, microscopy revealed luminally expressed integrin a5b1 
in the peri-infarct. This is evident by the representative open vessel in Figure 2.3A, 
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Figure 2.1: Integrin a5b1 increases following ischemic stroke. A. a5 positive pixel 
analysis on sham and PSD1-4 ipsilateral tissue. B. Representative image of A. 4x 
Magnification. Scale bar = 250 μm. 
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Figure 2.2: Integrin a5b1 is abluminally expressed in the stroke core. A. 
Representative 20x microscopy image of a core vessel. The red box shows 
representative images to the right. Green is a5, red is Collagen IV, and DAPI is 
blue. Scale Bar =50μm. B. Representative confocal microscopy of a core vessel. 
Green is a5 and red is Collagen IV. Scale bar = 20μm. 
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Figure 2.3: Integrin a5b1 is luminally expressed in the stroke peri-infarct. A. 
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Representative 20x microscopy image of a peri-infarct vessel. Ted box shows 
representative images to the right. Green is a5, red is Collagen IV, and DAPI is 
blue. Scale bar = 50μm. B. Representative confocal microscopy of a peri-infarct 
vessel. Green is a5 and red is Collagen IV. Scale bar = 20μm. 
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where the green a5 pixels are localized predominantly to the luminal space. 
Models using confocal microscopy with collagen IV (Figure 2.3B) confirmed this 
observation. Importantly, the amount of co-localizing pixels (yellow) was reduced, 
again suggesting the lack of integrin a5b1 in the extracellular space on the 
abluminal vasculature. 
 
Integrin a5b1 binds a unique ligand in the per-infarct 
As mentioned, countless examinations of integrin a5b1 binding have shown a high 
preference for fibronectin as a ligand binding partner (156), while other potential 
ligands have also been reported. Only the peri-infarct areas were examined due 
to lack of tissue/vasculature damage and consistent vascular shape. No co-
labeling was determined with integrin a5b1 and the potential ligands, plasma 
fibronectin (Figure 2.4A), fibrinogen (Figure 2.4B), and amyloid b (Figure 2.4C), 
suggesting no binding complexes are present in the peri-infarct.  
 
Discussion 
Here, we wanted to determine the therapeutic potential of targeting integrin a5b1 
in experimental ischemic stroke through expression and vascular location. We 
determined that 1) integrin a5b1 is upregulated acutely following stroke, 2) is   




Figure 2.4: Peri-infarct vessels show no integrin a5b1 binding to fibronectin, 
fibrinogen, or amyloid-b. A. Representative confocal microscopy image of a5 
(green) and red A. plasma fibronectin, B. fibrinogen, and C. amyloid-b. Scale Bar 
= 100μm. 
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 localized to the luminal vasculature in the per-infarct, but abluminal vasculature in 
the core, and 3) in the peri-infarct, integrin a5b1 does not bind plasma fibronectin 
in our cortically limited experimental ischemic stroke model. Furthermore, this is 
the first study of its kind to determine the vascular localization and binding partner 
of integrin a5b1 in experimental ischemic stroke. 
 
Based on the success of the a5 endothelial knockout mice, we intend to target 
integrin a5b1 therapeutically. To attempt this, we must first determine when 
integrin a5b1 is upregulated in our experimental stroke model. Though this has 
been explored in intraluminal suture models, the presentation is comparing white 
and gray matter, a significant enough difference that could affect temporal 
upregulation. Furthermore, the intraluminal suture model does not possess a peri-
infarct region with the expansive infarct volumes. This presentation does not model 
human stroke, nor the potential for expansion into this at-risk tissue. All of these 
factors in concession with the high variability of physiological changes can 
significantly affect the temporal expression. Even with multiple competing factors, 
the expression of integrin a5b1 in our model is consistent at PSD4. However, we 
  49 
did not extend observation through PSD7 and PSD14, so it is plausible the chronic 
expression is significantly different from these models. 
 
Targets of interest that are easily accessible to intravenous injections are of high 
demand, especially when targeting areas of the brain. The BBB is comprised of 
non-fenestrated endothelial cells, extracellular matrix and astrocytic endfeet, all 
working together to prevent movement of components from entering the cerebrum 
from blood (see Chapter 1 for more information). This hampers access of any 
therapeutics larger than 80 Da from accessing the target area, such as 
extracellular matrix, astrocytes and neurons. BBB dysfunction has also been 
implicated in expanding damage from the core intro the peri-infarct by allowing 
cytotoxic and vasogenic edema (16).  Interestingly, only integrin a5b1 in the peri-
infarct region of the stroke, is localized to the luminal vasculature and accessible 
to targeted therapeutics. On the other hand, integrin a5b1 is expressed in the 
abluminal compartment in the core, away from most therapeutics. This points 
toward the potential for binding of integrin a5b1 to a luminally expressed ligand 
promoting cellular migration. Another possibility is for bound/unbound integrin 
a5b1 to transcytose within intracellular vesicles, though the purpose for this 
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hypothesis is less evident. Once bound, integrin a5b1 can become endocytosed 
or aid in paracellular migration between endothelial cells to emerge in the 
abluminal space and associate with the extracellular matrix. Furthermore, the core 
integrin a5b1 expression appears to be outside therapeutic intervention, but early 
administration could potentially target a larger peri-infarct region, before damage 
has had time to spread.   
 
The localization of integrin a5b1 is not only vital for therapeutic intervention, but 
also for potential ligand partners. The preferential ligand for integrin a5b1 is 
fibronectin in the extracellular matrix, abluminally expressed. Thus, peri-infarct 
expressed integrin a5b1 would be unable to bind this fibronectin. Interestingly, 
there are two types of fibronectin, insoluble (basement membrane fibronectin) and 
soluble (plasma fibronectin). Both are potential integrin a5b1 ligands as both types 
of fibronectin include both the main binding site, RGD, and the synergy site, 
PHSRN. In fact, expression of plasma fibronectin has been shown to increase at 
PSD2 following experimental ischemic stroke, similar to the observed initial 
increase in expression of integrin a5b1 (79). As both types of fibronectin express 
the same RGD binding site for integrin a5b1, it was surprising that our 
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immunohistochemistry experiments showed no binding to plasma fibronectin in the 
peri-infarct. Next, we turned our attention to other vascular ligands shown to 
increase following stroke, amyloid b (160) and fibrinogen (161), and again found 
no obvious binding. When combining the luminal expression and lack of binding to 
common ligands of integrin a5b1, this supports the early stated hypothesis that 
integrin a5b1’s role following ischemic stroke is for cellular migration.  
 
In this study, we do have some limitations. First, our experimental design for 
integrin a5b1 expression after ischemic stroke only goes to PSD4, while other 
studies have shown peaking expression at PSD7 (46). As with the differences 
describe above, further experiments need to be performed at PSD7, PSD11, 
PSD14 to determine the chronic expression of integrin a5b1 in our experimental 
ischemic stroke model. Next, we use only one method of integrin a5b1 localization 
and ligand binding, immunohistochemistry. Processing tissue for 
immunohistochemistry involves sectioning and washing, potentially displacing 
expression of integrin a5b1. Thus, future studies involving electron microscopy 
and microvessel isolation could be used to further isolate both vascular localization 
and the ligand binding partner of integrin a5b1.  
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In conclusion, we determined that integrin a5b1 could be a therapeutic target 
following ischemic stroke based on acute increased expression on the luminal 
vasculature. Furthermore, once activated, integrin a5b1 bound to a unique ligand 
may induce cell migration, leading to vascular remodeling for angiogenesis.  
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Chapter 3: The inflammatory response after ischemic stroke: Targeting b2 
and b1 Integrins 
Danielle N Edwardsv and Gregory J Bix 
 
Introduction 
Ischemic stroke is a leading cause of death and disability in the United States with 
limited therapeutic interventions available, including tissue plasminogen activator 
(t-PA) and endovascular mechanical thrombectomy (1,3-4).  These interventions 
are focused on the removal of the thrombus, restoring blood flow, oxygen and 
glucose to hypoperfused areas, but are unable to affect the inflammatory, necrotic, 
and BBB mechanism that follow.  In particular, the initial inflammatory cascade is 
initiated by the decrease in ATP production, release of cytokines, influx of 
intracellular calcium, reactive oxygen species, etc. that develops during occlusion 
and continues for days afterword (16,162). Collectively, these processes promote 
recruitment and infiltration of marrow-derived leukocytes (including 
polymorphonuclear leukocytes (PMNs), neutrophils, lymphocytes and monocytes), 
which occurs almost immediately following reperfusion, as movement can only 
occur under shear forces from the re-established flow (163-167).   
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The initial endothelial response upregulates endothelial selectins, particularly P-
selectin and E-selectin, translocating them from an intracellular, inactive state, to 
the available extracellular matrix for leukocytic binding, while the upregulation of 
L-selectin on the leukocyte is essential for recruitment to the site of injury (168). 
Both are acutely regulated, P-selectin at 15 minutes and E-selectin at 2 hours post 
ischemia. These extracellularly located selectins then facilitate the recruitment and 
activation of leukocytes to the area of ischemia (169). Leukocytes then undergo a 
conformational change, facilitating polarization and the development of certain 
cellular characteristics: a leading edge, main body, and rear-uropod protrusion. 
The uropod in fast moving leukocytes promotes mobility, while the leading 
protrusions (lamellipodia and filopodia) are less likely to be used due to the rate 
limiting interaction with actin (170-171), though this mechanism is less obvious in 
the highly mobile leukocytes. Once leukocytes are bound to selectins, additional 
binding to integrins and adhesion molecules (intracellular adhesion molecule 
(ICAMs and vascular adhesion molecule-1(VCAM) occurs, permitting leukocytic 
rolling (172-175). Additional damage can occur once at the site of ischemia, as 
infiltration into the brain parenchyma across the BBB destroys surrounding 
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vasculature (176), and leukocytes continually release additional factors (reactive 
oxygen species, cytokines, and proteases) that enhance leukocytic recruitment 
(177).  
 
At the site of injury, leukocytes continue to increase binding on cerebrovasculature 
up to 48 hours following ischemic stroke. Early adhesion, prior to 24 hours 
following reperfusion, is attributed to neutrophils. Within 30 minutes to a few hours 
following reperfusion, neutrophils arrive at the site of injury, peaking at maximum 
expression around 1-3 days, though expression can still be detected 7-15 days 
later in preclinical stroke models (178). This upregulation is also seen in ischemic 
stroke patients, where neutrophils have been detected beginning at 6 hours, with 
radiolabeled imaging, and continue to be detected up to 72 hours (179).  The early 
recruitment and infiltration of neutrophils across the BBB appears to be highly 
significant in stroke, as high neutrophilic infiltration is associated with damaged 
cerebrovasculature (180), while depletion reduces infarct volume and dysfunction 
in stroke models (181).  
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As reperfusion injury continues, the circulating leukocytes switch from neutrophils 
to mononuclear leukocytes (monocytes/lymphocytes) dominate the adherent 
culture from 24 hours to 7 days post reperfusion (182-184). Of the two types of 
lymphocytes, B- and T-, T cells have emerged as the dominant, damage-inducing 
lymphocyte in ischemic stroke (185). Preclinical studies have shown the inhibition 
of all lymphocytes results in smaller infarct and improved neurological outcomes, 
but only the reintroduction of T-lymphocytes to mice reversed any benefits (186-
188).  Activated T-lymphocytes, not B-, have also been detected in patients up to 
60 days post-stroke, and are correlated with an increased risk of stroke 
reoccurrence and death (189-190).  
 
Multiple studies have established the importance of leukocytic adherence and 
infiltration into the brain parenchyma following ischemic stroke, but targeting the 
leukocytes has a high degree of risk. This is evident as inhibition of leukocytic cells 
increase the occurrence of bacterial and mortality as evident by Leukocytic 
Adhesion Deficiency (LAD-1) (164). Because these cells are necessary for 
bacterial resistance, systemic inhibition following ischemic stroke is exceptionally 
risky. Current attempts at targeting the inflammatory cascade have focused on the 
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adhesion and infiltration of cells at the site of injury, primarily endothelial expressed 
ICAMs and VCAM. This method has shown success in preclinical studies, but 
failure once translated to the clinic (as discussed below). Thus, more focus has 
been placed on targeting integrins, a primary mediator of leukocyte adhesion. This 
review is focused on integrins, b2 and b1, that have shown promise in 
therapeutically targeting the ischemic stroke inflammatory cascade.  
 
Integrins: An overview 
Integrins are a diverse group of heterodimers composed of 18 different a and b 
subunits, creating 24 unique combinations (191). Integrins exist on every cell type, 
while exhibiting a high diversity of ligands, from RGD (Arg-Gly-Asp), laminin, and 
leukocytes, though many integrins have a high variety of potential ligands 
depending on the cellular environment. Under normal cerebrovascular conditions, 
integrins are in a highly inactive state, typically in a bent conformation (192). 
Following ischemic stroke, activation signals are sent. Chemokines are 
translocated to the lumen, on the apical side of endothelial cells, to induce “inside-
out” signaling (193-194). Integrins then undergo a conformational change to 
increase integrin affinity for potential ligands and are expressed on the either the 
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leading or rear-facing edge of the leukocyte’s cell wall for ligand detection 
(171,195). Activated integrins then bind to available ligands, permitting leukocytic 
rolling and intracellular signaling, termed “outside-in” signaling (193,196). 
Leukocytes continue movement to the site of injury, looking for areas to cross the 
endothelial cell barrier, and eventually coming to a halt. Aggregation/clustering of 
integrins increases binding avidity (strength of binding), preventing flow conditions 
from detaching leukocytes from the endothelial cells (193,197). Through 
transmigration, leukocytes will infiltrate into the cerebral parenchyma using these 
integrin-ligand connections.  
 
b2 integrins 
b2 integrins are the only group of integrins exclusively expressed on leukocytes 
(derived from hematopoietic cells) (198), and like most integrins, are highly 
conserved across species (199). They are also the most highly expressed integrin 
on circulating blood leukocytes, tending to cluster at the retraction area of the cell 
(the rear), in both an active and inactive state, compared to other b1, b4, b3, and b7 
integrins found on circulating leukocytes (200-201). Genetic leukocyte adhesion 
changes (LAD-1, as discussed above), have been attributed to mutations in the b2 
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subunit, reducing b2 expression. Thus, leukocytic movement is reduced on the cell 
surface and less movement toward the site of inflammation (164). Importantly, in 
b2 inhibited mice, there is not total arrest of leukocytic recruitment or infiltration 
(201), suggesting that other factors likely play a role.  There are 4 identified 
heterodimers of b2 integrins, aLb2, aMb2, aXb2, and aDb2 (36). Of these, the most 
highly studied are aLb2 and aMb2 in ischemic stroke, and will be the reviewed in 
more detail below.  
 
aLb2  
Integrin aLb2 is also referred to as CD11a/CD18 and LFA-1 (lymphocyte functional-
associating antigen-1). aLb2 integrin acutely increases in ischemic stroke patients, 
with detectable amounts through 72 hours associated around the area of ischemia 
(202-203). This suggests a correlation between aLb2 integrin expression and 
inflammatory damage following ischemia. Though its name suggests otherwise, 
aLb2 is expressed on all leukocytes (204), though at particularly high expression 
on T-lymphocytes (205-206). After ischemic stroke, aLb2 activation requires 
leukocytic rolling on P- or E-selectins, inducing an active conformational change 
(207), but it is the binding of chemokines g-protein coupled receptors (GPCR) and 
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Rap-1 activation that induces the high-affinity conformational state of aLb2 (208-
210). In this state, aLb2 has many possible ligands, ICAM-1, ICAM-2, ICAM-3, 
ICAM-4, ICAM-5, and junctional adhesion molecule-1 (JAM-1) (211-214), though 
ICAM-1 is preferentially bound (206). Once bound to high avidity aLb2-ICAM-1 
complexes form, T-lymphocytes are able to move against circulatory flow and 
shear forces, resulting in high-speed movement of leukocytes (215-216).  
 
In experimental models of ischemic stroke, aLb2 inhibition through therapeutic 
targeting and genetic manipulation result in reduced infarct volume, edema volume 
and mortality, though this phenomenon is evident in transient but not permanent 
middle cerebral artery occlusion (217-219). This may be due to the high avidity of 
aLb2-ICAM-1 bonds that allow for movement against circulatory flow. This is 
evident in aLb2 (LFA-1) knock-in mice that experience high avidity through tight 
binding of lymphocytes through ICAM-1 binding as expected, but are unable to 
continue movement due to a non-polarized uropod (220). An explanation for this 
phenomenon may be that the recycling process within the leukocyte is 
overwhelmed (221). By enhancing aLb2 expression, recycling may not be able to 
allow for dislocation of aLb2-ICAM-1 complexes, preventing movement from the 
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loss of high adhesion bonds. Enhanced aLb2 expression could be a potential new 
avenue for therapy, especially if no enhanced mortality, infection, etc. are observed. 
 
Independently, ICAMs play a significant role in inflammation following ischemic 
stroke. ICAM-1, in particular, is acutely increased in both cultured human 
endothelial cells and following experimental middle cerebral artery occlusion, while 
expression remains sustained for up to a week post-injury (222-225). While ICAM-
2, another possible ligand, does not change in expression following reperfusion 
(226). Furthermore, serum of ischemic stroke patients contains soluble ICAM-1, 
but not ICAM-2 in addition to being a risk factor (227-228). Antibodies targeting 
ICAM-1 in rodents and humans have shown contradictory results. In rodents, mice 
and rats showed a decrease in leukocyte infiltration and infarct volume (229-231), 
while one study reported opposing effects (232). ICAM-1 inhibition was translated 
to the clinic through testing of the murine ICAM-1 antibody, Enlimomab in ischemic 
stroke. Unfortunately, the study was halted early due to increased rate of infection, 
infarct volumes, neurological scores and mortality for patients (232).  
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aMb2 
Integrin aMb2 is also known as CD11b/CD18 and Mac-1 (macrophage-1 antigen). 
Integrin aMb2 has many similarities to aLb2, through its expression on all leukocytes 
(233), and common ligand binding partners such as the family of ICAMs and JAMs 
(234). Additional ligands are fibrinogen, heparin (234), elastase (235), complement 
C3 fragment (C3bi) (236), kinogen components, and urokinase and its receptor 
(237). Just as aLb2, hypoxia induced factors (cytokines, chemokines, etc.) induce 
conformational change of aMb2 to a high affinity ligand-binding state (238). Binding 
assays with ICAM-1 as a ligand and both aLb2 and aMb2 show aLb2 integrin is 
preferably bound (239). This suggests that the binding sites on both aLb2 and aMb2 
compete for ICAM-1 binding. 
 
Following experimental ischemic stroke in rats, integrin aMb2 is upregulated (240), 
and has shown benefit when inhibited. Antibodies against both CD11b/CD18 
reduce infarct volume and reestablished cerebral blood flow as a result of 
decreased neutrophil infiltration (225,241-242). In a different approach, the 
addition of recombinant neutrophil inhibitory factor (rNIF) inhibits a binding domain 
on Mac-1 and yields similar results (243). Furthermore, similarly to aLb2 integrin 
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inhibition, inhibition of aMb2 is also effective in transient, but not permanent 
experimental ischemic stroke (244). 
 
Clinical Implications 
With many successful preclinical trials, across multiple laboratories, clinical trials 
were instigated to target b2 integrins. Importantly, no clinical stroke trials to date 
have targeted the aL subunit. Though one clinical trial with the monoclonal antibody, 
Efalizumab, has shown promise in decreasing T-lymphocyte rolling in patients with 
moderate-severe plaque psoriasis (245).  
 
In preclinical studies targeting aMb2, a hookworm isolated recombinant 
glycoprotein targeting rNIF (UK279276) (244) and humanized Hu23F2G 
(Leukarrest) (246), were both shown to decrease infarct volume and increase 
functional recovery following reperfusion.  Both therapies had negligible side 
effects in Phase 1 studies and thus were continued to a Phase II study, respectively, 
before the trials were halted due to no observed efficacy (247-248). The failure to 
target aMb2 integrin may be due to the observation that human ischemic stroke 
patients do not experience the increase in aMb2 expression, compared to rodent 
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models (249). Interestingly, when given in conjunction with UK279276, patients 
experienced a slight improvement (248), but no follow-up has been conducted. 
This interesting effect may be worth additional investigation in future clinical trials.  
 
b1 integrins 
b1 integrins are a diverse set of integrins, with laminin-binding, collagen-binding, 
RGD-binding and leukocyte heterodimers (226). b1 integrins are not as highly 
expressed on leukocytes as b2 integrins, but they do play a major role in leukocyte 
adhesion and migration following ischemic stroke. The activity of b1 integrins is 
similar to b2 integrins. They undergo a conformational change to induce “inside-
out” and “outside-in” cellular signaling (250). As the cells migrate, the b1 integrins 
are most commonly clustered around the uropod, but will be located in any area of 
the leukocyte that is in contact with the endothelial cell or extracellular matrix (249-
250). Inhibition of the b1 integrin, just as with b2 integrin inhibition, does not fully 
stop leukocyte rolling. However, when both b1 and b2 integrins are inhibited, 
complete leukocyte arrest occurs (201,251). This suggests that both b1 and b2 
integrins are necessary for leukocyte migration, regardless of expression load. Of 
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all the b1 integrins, both a4b1 and a5b1 appear to be the most highly expressed and 
the most studied in inflammatory states. 
 
a4b1  
a4b1 is also known as CD49d/CD29 VLA-4 (very late antigen-4). Besides 
dimerizing with b1, localizing to leukocytes and microglia, a4 will also dimerize with 
b4, which is found in gut endothelium (205). Activation of a4b1 integrin results from 
the binding of upregulated chemokines to GPCRs in the same manner as aLb2 as 
discussed above (252). This stimulates binding to a4b1’s preferred ligand, VCAM-
1, but experiments have shown some preference for paxillin and ICAM-1 as well 
(208,210). Interestingly, instead of using the b1 submit of the heterodimer for 
binding, integrin a4b1 uses its a subunit of a4b1 to mediate binding to VCAM-1 253).  
  
Preclinical ischemic stroke studies targeting a4b1 have shown increasingly varied 
results. Most researchers reported a decrease in VCAM-1 expression, cytokine 
production, and infiltrating leukocytes (254-256), but this reduction in inflammation 
did not result in reduced infarct volumes or functional deficit (256). Langhauser et 
al went one step further and found that no treatment paradigm (prophylactic or 
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therapeutic) and no model (transient or permanent) showed efficacy (255). On the 
other hand, both Becker (247) and Relton (257) found that inhibition of a4 improved 
both infarct volumes and functional deficits. When a preclinical randomized control 
trial was implemented at multiple centers, researchers found efficacy only in 
patients with small infarct volumes (256). Collectively, these contradictory results 
may be caused by a couple of scenarios, 1) the varying expression of integrin a4b1 
expression following ischemic stroke resulting in continued leukocyte infiltration, or 
2) integrin a4b1 is not a primary driver of post-stroke pathophysiology, but other 
factors, including other integrins, promote leukocyte migration (205). 
 
a5b1 
a5b1 is also known as CD49e/CD29 and VLA-5. Unlike the previously mentioned 
integrins, not much is known about a5b1 integrin’s role in inflammation, and what 
is known is limited to cell culture. We do know that leukocytes express different b1 
integrins with a5b1 composing around 50% of all b1 –integrins expressed, and a5b1 
is necessary for leukocyte adhesion. Only inhibition of both a5b1 and b2 integrins 
completely blocks adhesion (201), while inhibition of a5b1 alone prevents 
transmigration across the BBB (258). Fibronectin is a5b1’s main ligand, and in the 
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presence of activated aLb2, leukocyte, its binding to a5b1 is enhanced (259-261). 
a5b1 integrin expression is induced by cytokines, particularly TNFa (81) toward the 
leading edge of the cell in contrast with other integrins at the uropod (201). 
Furthermore, a5b1 integrin appears to be highly sensitive to calcium (201,262), an 
ion that is increased rapidly following reperfusion (16). Upon calcium buffering, 
a5b1 expression moves from the front of the cell to the uropod and the leukocyte 
becomes elongated. The change in expression localization and morphology is 
attributed to non-movement as the leukocyte cannot detach a5b1 from the vascular 
wall (201). Recently, Edwards et al found inhibition of a5b1 integrin by the small 
peptide ATN-161 prevented CD45+ leukocytes from infiltrating the brain 
parenchyma. Additionally, mice had reduced BBB permeability, functional deficits, 
edema, and infarct volume following middle cerebral artery occlusion (263). Thus, 
targeting a5b1 after ischemic stroke could be a new avenue for reduction of 
inflammation following ischemic stroke. 
 
Clinical Implications 
Even though the results on blocking b1 integrins are small and varied, one clinical 
trial has emerged targeting a4b1 in the context of ischemic stroke. The monoclonal 
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antibody targeting the a4 subunit (Natalizumab) has been successful in protecting 
patients from relapses in multiple sclerosis (264) and Crohn’s disease (265). In a 
Phase II study, patients receiving Natalizumab showed no improvement in infarct 
growth or neurological scores over 30 days. Furthermore, two patients (out of 79) 
died from serious infections attributed to Natalizumab treatment (266). At this time, 
there are no further clinical trials planned. 
 
Conclusion 
In this review, we have implicated integrins as an area of research for limiting 
inflammation following stroke (reviewed in Figure 3.1). To date, therapeutic 
inhibition of aLb2, aMb2, and a4b1 has shown promising results in preclinical studies, 
but translation to the clinic has been disappointing. Going forward, more targeted 
antibodies to all reactive b1 and b2 integrins after ischemic stroke may prove more 
beneficial, but more research needs to be done to completely understand the 
human inflammatory response and how that relates to changes in preclinical 
models.  
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Figure 3.1: Representative image of integrin response following stroke and the 
effects of inhibitory antibodies. 
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Chapter 4: Integrin a5b1 inhibition by ATN-161 reduces blood-brain barrier 
permeability, neuroinflammation, and is neuroprotective follwoing ischemic 
stroke 
Danielle N Edwards, Kathleen Salmeron, Douglas E Lukins, Amanda Trout, Justin 
F Fraser, and Gregory J Bix  
 
Introduction 
Acute treatment for ischemic stroke is currently limited to 
recanalization/reperfusion strategies only provided to a minority of patients: 
intravenous tissue plasminogen activator (t-PA) and/or endovascular 
thrombectomy (1,267-269). While these treatments remove the blood vessel-
obstructing thrombus, they fail to impact secondary reperfusion injury. Reperfusion 
injury results from an influx of factors including calcium, cytokines, reactive oxygen 
species, growth factors, matrix metalloproteinases (MMPs), and other damaging 
proteins that induce extracellular matrix (ECM) degradation, leukocyte infiltration, 
and apoptotic cascades (16,226). These processes destabilize the blood-brain 
barrier (BBB), a vascular defense mechanism composed of non-fenestrated 
endothelial cells tightly bound by tight junction (TJ) proteins and junctional 
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adhesion molecules (JAMs), that are surrounded by astrocytic endfeet16,226,270). 
Collectively, this results in an increase of the infarct volume from the site of the 
initial injury (core) into the surrounding at-risk tissue (peri-infarct). Therefore, 
targeting reperfusion injury could alter ischemic stroke outcomes. 
 
One such potential target is the integrin receptor family, a group of cell surface 
transmembrane glycoprotein receptors for the ECM composed of non-covalently 
bound α and β subunits. Vital to stroke pathophysiology, integrins have been 
implicated in cell migration, cellular adhesion, and cellular survivability (271-272). 
Previously, our laboratory has shown that elimination of the specific pro-angiogenic 
integrin α5β1 in endothelial specific knockout (α5KO) mice results in significance 
resistance to ischemic stroke injury. Furthermore, these α5KO mice maintained 
near-baseline pre-stroke levels of the TJ protein claudin-5 and exhibited little to no 
disruption of the BBB barrier (65). These results, combined with previous studies 
demonstrating a sustained increase in the post-stroke expression of integrin 
α5β1(63,273), suggest that inhibition of α5β1 integrin could be therapeutic by 
stabilizing the BBB. Early intervention of the BBB following ischemic stroke is ideal, 
as its role in injury is not immediately apparent (274). To that end, in this study we 
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use the small peptide non-competitive integrin α5β1 inhibitor, ATN-161, in a 
mouse model of ischemic stroke. ATN-161 is a non-competitive inhibitor targeting 
the integrin α5β1  allosteric site, PHSRN (Proline-Histidine-Serine-Arginine-
Asparagine), instead of the main RGD binding site. Importantly, ATN-161 was safe 
and well-tolerated in a number of Phase I and II clinical oncology studies (159), 
supporting its potential as a ‘shovel-ready’ clinical stroke therapeutic.  
 
Materials and Methods 
Animals 
All animal studies were approved by the Institutional Animal Care and Use 
Committee (IACUC) of the University of Kentucky prior to their performance. 3-
month old C57/Bl6 (The Jackson Labs, Bar Harbor, Maine, USA) were housed in 
14-hour day/light cycles under free feeding conditions 10 days before being used 
in experiments.  
 
Stroke Surgery 
C57/Bl6 wild-type, male mice underwent transient tandem ipsilateral common 
carotid artery / middle cerebral artery (CCA/MCA) occlusion for 60 minutes as 
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previously published (65), followed by reperfusion for 1-3 days. Briefly, a small burr 
hole is created directly over the M2 branch of the MCA, and a metal filament, 
diameter 0.0005 inch, is placed under the artery on both sides of the burr hole. The 
CCA was then isolated and occluded using an aneurysm clip. Blood flow was 
determined with the Laser Doppler Perfusion Monitor (Perimed, Ardmore, PA, 
USA). Animals that received less than 80% occlusion rate from baseline (i.e. pre-
occlusion) were excluded from analysis. Sham animals underwent the listed 
procedure without vascular occlusion. All mice were allowed to recover to PSD3, 
during which daily body weights were measured.  
 
ATN-161 Preparation 
ATN-161 (Medkoo Biosciences, Inc, Morrisville, NC, USA) is stored as a 
lyophilized powder at -20C. On the day of treatment, ATN-161 is solubilized in PBS, 
kept cold on ice until use not exceeding 3 hours later. A new vial of ATN-161 is 
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Physiological Measurements 
Immediately following reperfusion, heart, rate, pulse distension, and body 
temperature were recorded using MouseOx (Starr Life Science, Holliston, MA, 
USA). After 5 minutes, sterile PBS (Vehicle) or ATN-161 was injected via IP (as 
described below); mice were continually observed for 15 minutes post reperfusion.   
 
Animal Treatments 
Animals received an IP injection of either Vehicle or ATN-161 (1mg/kg (156) in 
sterile PBS, Medkoo Biosciences, Morrisville, NC, USA) immediately after 
reperfusion, PSD1 and PSD2. Ischemic stroke was confirmed on 2mm sections 
stained with 2,3-triphenyltetrazolium chloride (TTC; BD, Sparks, MD, USA) or 
Magnetic Resonance Imaging on PSD3. Accounting for edema volume, infarct size 
based on TTC images was analyzed with Image J (NH) software as: 
Infarct	volume = infarct	x	(Contralateral	HemisphereIpsilateral	hemisphere ) 
Animals were excluded from the study if the CCA and/or MCA was punctured 
during wire and clamp placement or removal.  
 
 
  75 
Magnetic Resonance Imaging (MRI) 
PSD3 animals were anesthetized with isoflurane and placed on a heated bed 
where body temperature and breathing rate were carefully monitored throughout 
the scan. All images were performed by a Bunker/Siesman 7Tesla MR in the 
University of Kentucky Magnetic Resonance Imaging and Spectroscopy Center.  
T1 and T2 weighted images of the brain were obtained in the transverse plane 
without intravenous contrast. Additionally, Apparent Diffusion Coefficient (ADC) 
images were produced in the transverse plane using Diffusion Tensor Imaging 
(DTI). All images were analyzed with ITK-SNAP (275) (www.itksnap.org) by a 
blinded, independent neuroradiologist. Edema and infarct volume were 
determined by software based manual segmentation. Infarct enhancement was 
calculated by analysis of absolute signal intensity on T1 weighted images before 
and after the administration of gadolinium based contrast material. 
 
Tissue Histology and Immunohistochemistry 
On PSD3, animals were systemically perfused with PBS (Phosphate Buffered 
Solution, 1X) for 5 minutes. Brains were removed, flash frozen in liquid nitrogen, 
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and stored at -20C until use. The brains were sectioned by cryostat at 20µm and 
mounted on slides for staining.  
 
IgG Immunohistochemistry 
Sections were fixed in 10% phosphate-buffered formalin. After washing, IgG 568 
biotinylated antibody (1:500, Thermo-Fisher Scientific) in 1% bovine serum 
albumin was applied to the tissue for 2 hours. Slides were then cover slipped 




Sections were fixed in methanol:acetone (1:1), followed by blocking buffer (5% 
bovine serum albumin (Fisher Scientific) in PBS with 0.1% Triton-X). Sections were 
incubated in primary antibody overnight at 4C (anti-rabbit PECAM at 1:100, Fisher 
Scientific; anti-rat CD49e at 1:250, BD Pharminagen; anti-rat CD45 at 1:200, 
ThermoFisher Scientific; and anti-rabbit Claudin-5 at 1:200, Abcam). Sections 
were washed and placed in fluorophore-conjugated secondary antibody at room 
temperature (Vector Labs, 1:250). Sections were washed and incubated with 
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NucBlue (Fisher Scientific), cover slipped (Vector Labs) and imaged on a Nikon 
Eclipse Ti and software (Nikon, Melville, NY, USA). 
 
Behavioral Testing 
Stroked mice underwent an 11-point behavioral neurological score behavioral 
assessment on PSD0 (Baseline prior to drug administration), PSD1, 2, and 3 to 
assess the following behavioral metrics: level of consciousness (LOC), gaze (G), 
visual field (VF), sensorimotor response (SR), grip strength and endurance/ 
paralysis paw hang (PPH). LOC was determined as natural movement prior to any 
cage disturbance. A severity score of 0-2 was assigned, 0 being alert and active, 
1 alert upon stimulation, and 2 for being hunched, unstimulated, and loss of 
grooming. Gaze was assessed by waving an object in front of each eye without 
disturbing the whiskers. Based on a severity score of 0-1, 0 was given if they 
recognized the sign by turning their head, and a 1 was given if no response was 
noted. VF was assessed holding the mouse vertically next to a platform by the tail 
(both right and left sides). A score of 0 was given if the mouse reached for the 
platform, and a 1 for failure to do so. SR was scored by pressing each paw in turn 
to elicit vocalization, paw retraction, or jumping as a reaction to pressure.  A score 
  78 
of 0 was given for exhibiting a reaction, and a 1 for no reaction. Finally, PPH was 
scored by a paw hang test. Only front paws were used for gripping of a rod while 
being supported by a hold on the tail for 60 seconds. A score of 0 was given for 
completion of the full 60 seconds, a 1 for any dropping of a paw without full loss of 
contact, and a 2 for a fall. The total scores are tallied at the conclusion of the testing 
to assess overall function.  
 
Gene Expression 
On PSD3, brains were removed and sectioned at 2mm where the ipsilateral 
cortical tissue and corresponding contralateral cortical tissue were isolated. All 
sections per animal were combined and homogenized in Trizol (Life Technologies). 
RNA extraction was performed according to the RNA extraction kit provided by the 
manufacturer (Life Technologies). RNA was converted to cDNA using a high 
capacity cDNA reverse transcriptase kit (Applied Bioscience, Grand Island, NY, 
USA). 18S (control), claudin-5, IL-1𝛽, CXCL12, and MMP9 genes were analyzed 
using Real-time PCR (ViiA7, Life Technologies). Data was analyzed as fold 
change comparing vehicle and ATN-161 treated mice as a % control (sham). 
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Blinding and Randomization 
All experiments and data analysis were conducted in a blinded and randomized 
(using an online randomization generator).  
 
Statistical Analysis 
 All measureable values are presented as mean ± SEM. Sample size was 
determined for 80% effect by power analysis. Comparisons between Vehicle and 
ATN-161 treatment were performed using a Student’s t-test. For multiple 
comparisons, a two-way repeated measures ANOVA was used with the posthoc 
Bonferroni test. Significance is determined as p*<0.05, p**≤0.01, p***≤0.001, and 
p****≤0.0001. Outliers were determined by the interquartile range (IQR). 
 
Results 
ATN-161 treated mice show reduced infarct size following experimental ischemic 
stroke  
First, we examined whether acute, post-reperfusion IP ATN-161 administration 
was safe. ATN-161 treated animals did not show any differences in weight (Figure 
4.1A), body temperature (Figure 4.1B), heart rate (Figure 4.1C), or pulse  
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Figure 4.1: Systemic effects of ATN-161 administration. A. Percent change of 
weight (g) through PSD3. B. Percent change of body temperature (℃) following 
reperfusion. C. Percent change of heart rate (bpm) following reperfusion. D. 
Percent change of pulse distension (μm) following reperfusion.  
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distension (Figure 4.1D) following ischemic stroke compared to Vehicle treated 
stroked controls.  
 
Once safety was determined, stroked mice were IP administered Vehicle or ATN-
161 immediately after reperfusion, on PSD1, and PSD2 (Figure 4.2A).  By TTC 
assessment, mice treated with ATN-161 had smaller infarcts on PSD3 (Figure 4.2B 
and Figure 4.2C; p=0.0004; ATN-161 16.37±4.113, n=12; Vehicle 35.41±4.054, 
n=12).  
 
To further confirm potential ATN-161 effects on infarct volume in a translationally 
relevant manner, stroked mice underwent DTI imaging on PSD3. Infarct volume 
was again shown to be reduced in ATN-161 treated mice (Figure 4.3A and  
Figure 4.3B; p=0.0220; Vehicle 17.9±1.768, n=7; ATN-161 12.24±1.329, n=8). 
Collectively the TTC and DTI analysis shows a decrease in infarct volume following 
ATN-161 treatment. 
 
ATN-161 administration reduces edema following experimental ischemic stroke 
  
 





Figure 4.2: ATN-161 reduces infarct volume and improves functional recovery. A. 
Injection schematic B.  Representative images of C. TTC analysis of infarct volume 
at PSD3. Images has been altered to line up the sections. 
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Figure 4.3: ATN-161 reduces MRI infarct volume and edema. A. Representative 
DTI images. B. DTI analysis for infarct volume. Arrows indicate infarcted region. C. 
Representative T2-weighted MRI images. Arrows indicate edematous region. D. 
T2-weighted MRI analysis for edema volume.  
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In addition to infarct volume, we also determined the extent of post-stroke edema 
with T2-weighted MRI. Imaging showed a reduction in edema in ATN-161 treated 
mice (Figure 4.3C and Figure 4.3D; p=0.0097; Vehicle 15.12±1.212, n=7; ATN-
161 8.777±1.647, n=8). Interestingly, the ATN-161 treated mice, but not the  
Vehicle group, showed a linear correlation relationship between infarct volume and 
edema volume (Figure 4.4C; ATN-161 p=0.0072, 𝑅= =0.7264) (Figure 4.4B; 
Vehicle p=0.0786,	𝑅==0.4931) (All treatments, Figure 4.4A). This suggests that 
integrin α5β1 plays a role in the extent of edema following ischemic stroke. 
 
ATN-161 treated mice have better functional outcomes  
ATN-161 treated mice showed less functional deficit on PSD3 by Neuroscore 
(Figure 4.5A; p=0.0002; Vehicle 2.286±0.19, n=14; ATN-161 3.286±0.22, n=14), 
while there is no difference on PSD1. 
 
ATN-161 reduces α5β1 expression following ischemic stroke 
 α5β1 integrin expression decreased at PSD3 with ATN-161 administration in both 
the peri-infarct (Figure 4.5B and Figure 4.5D; p=0.0835, Vehicle 308484±72853, 
n=7; ATN-161 162166±26469, n=7) and core (Figure 4.5C and Figure 4.5D;  




Figure 4.4: ATN-161 influences edema volume. A. Linear correlation of infarct 
volume and edema volume for all treatments. B. Linear correlation of infarct 
volume and edema volume for Vehicle treated animals. C. Linear correlation of 
infarct volume and edema volume for ATN-161 treated animals.  
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Figure 4.5: ATN-161 reduces integrin α5β1 expression. A. 11-point Neuroscore 
analysis at baseline, PSD1, and PSD2. Analysis of integrin α5β1 at PSD3 in the B. 
core and C. peri-infarct. D. Representative images for B. and C.10x magnification, 
scale bar = 100μm.  
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p=0.3138, Vehicle 332114±7915, n=7; ATN-161 233111±51006, n=7) regions of 
the stroke, although these differences were not significant. Interestingly, ATN-161 
had an increased effect on α5β1 integrin expression in the region ventral to the 
injury (Figure 4.6A; Figure 4.6B; p=0.1092; Vehicle 384123±106607, n=7; ATN- 
161 190693±33630, n=7) compared to the region dorsal to the injury (Figure 
4.6C)p=0.0340; Vehicle 212647±28412, n=7; ATN-161 126903±21841, n=7). 
 
ATN-161 reduces BBB permeability following experimental ischemic stroke 
Since α5KO mice showed a stabilized BBB after experimental stroke10, we next 
determined BBB stability via brain IgG extravasation following ATN-161 
administration.  ATN-161-treated animals had significantly less parenchymal IgG 
extravasation in the ischemic core (Figure 4.7A and Figure 4.7B; p=0.0234; 
Vehicle 70125±20216, n=7; ATN-161 16753±8255, n=8). Interestingly, ATN-161 
treated mice experienced a correlation between IgG extravasation (i.e. degree of 
BBB opening) and edema (Figure 4.7D; p=0.0590, 𝑅==0.474) that was lost with 
Vehicle treated mice (Figure 4.7C; p=0.3705, 𝑅= =0.1621). However, IgG 
extravasation and infarct volume did not correlate in either Vehicle (p=0.9732, 
𝑅==0.0002498) or ATN-161 (p=0.1309, 𝑅==0.3377) treated mice. This suggests a 
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Figure 4.6: Integrin α5β1 expression in the peri-infarct region. A. Representative 
image for region of interest dorsal (blue) and ventral (green) to the core (pink). 









Figure 4.7: ATN-161 reduces BBB permeability following ischemic stroke. A. 
Representative images of A. 20x magnification, scale bar = 50μm. B. Analysis of 
IgG positive pixels in the core. C. Linear correlation between IgG positive pixels 
after vehicle treatment and Edema Volume. D. Linear correlation between IgG 
positive pixels after ATN-161 treatment and Edema Volume. 
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direct role for integrin α5β1, and its blockade, in determining the amount of edema 
following ischemic stroke due to regulating dysfunction of the BBB. Collectively, 
reduced infarct volume may be a consequence of inhibition of integrin α5β1 
through a less permeable BBB, and thus reduced edema. 
 
Next, to determine integrin α5β1's role in cerebrovascular pathology after stroke, 
we analyzed changes in vascular ECM proteins, proteinases that degrade the 
ECM, and TJs. On PSD3, Vehicle treated mice exhibit decreased collagen IV (an 
abundant ECM protein that is essential to BBB health) transcription compared to 
sham (p*=0.0115) and ATN-161 (p=0.0217) treated animals (Figure 4.8A; Sham 
1.018±0.07867, n=4; Vehicle 0.3543±0.03829, n=7; ATN-161 0.8563±0.2439, 
n=8), while ATN-161 treated animals were recovered to sham levels (p=0.7272).  
We next determined that MMP-9 (an ECM proteinase that typically increases after 
stroke) levels are increased in Vehicle treated animals compared to Sham 
(p=0.0028) and ATN-161 (p=0.0156) treated mice (Figure 4.8B; Sham 
1.018±0.08797, n=4; Vehicle 6.761±2.011, n=7; ATN-161 2.757±0.9076, n=7), 
though no significance between Vehicle and ATN-161 treated mice (p=0.5238).  
 
  91 
 
 
Figure 4.8: ATN-161 stabilized cerebrovasculature following ischemic stroke. A. 
qPCR analysis of ipsilateral cortex at PSD3 for collagen IV. B. qPCR analysis of 
ipsilateral cortex at PSD3 for MMP-9. C. Representative images of D. 10x 
Magnification, scale bar = 100μm. D. Analysis for Claudin-5 positive pixels in the 
core at PSD3.  
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Finally, we determined that ATN-161 treatment resulted in an increase of claudin-
5 in the core (Figure 4.8C and Figure 4.8D; p=0.0270; Vehicle 19830±2477, n=5; 
44220±8115, n=6). Collectively, inhibition of  α5β1 by ATN-161 stabilizes the 
vasculature at the site of injury (increased collagen IV, MMP-9, and claudin-5 
expression) and results in a more intact BBB (less IgG extravasation) following  
ischemic stroke. 
 
ATN-161 reduces the inflammatory response in the infarcted region 
Inflammatory cascades occur acutely and last for up to a week after stroke. This 
involves an increase in inflammatory cytokines and neutrophil infiltration, all 
localized to the core site of injury (16). Furthermore, integrins have been implicated 
in many inflammatory processes (272). To determine ATN-161’s potential effects 
on post-stroke inflammation, we first determined its effects on the expression of 
the master inflammatory cytokine, IL-1β, which is well known to be upregulated 
after experimental ischemic stroke (276). Indeed, we determined that IL-1 β 
transcription is increased in the Vehicle treated mice compared to sham (Figure 
4.9A; p=0.0006; Sham 1.023±0.0833, n=4; Vehicle 27.04±7.057, n=8). ATN-161 
administration, significantly reduced (p=0.0192; ATN-161 11.89±3.491, n=7)  
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Figure 4.9: ATN-161 reduces inflammatory cells after experimental ischemic 
stroke. qPCR analysis of ipsilateral cortex at PSD3 for A. IL-1β and B. CXCL12. 
C. Representative images of D. 4x Magnification, scale bar = 250μm. D. Analysis 
for CD45 positive pixels at PSD3.  
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(Figure 4.9A) IL-1β expression. Investigating the chemokine ligand 12 (CXCL12), 
previously shown to be protective following ischemic stroke (277), we found that 
Vehicle treated mice had reduced transcription of CXCL12 compared to sham and 
ATN-161 (Figure 4.9B; p=0.0022; Sham 1.015±0.09819, n=4; Vehicle 
0.5271±0.06725, n-7; ATN-161 0.8488±0.1006, n=8), while ATN-161 treated mice 
recovered CXCL12 to sham levels.  
 
Additionally, integrins have not only been implicated in cytokine and chemokine  
expression, but also in migration of inflammatory neutrophils to the site of injury, a 
mechanism highly implicated in edema and expansion of the core (16,226). Even 
though neutrophils have the highest significance of all leukocytes trafficking to the 
site of injury, all categories of leukocytes have a role (156). Because of this, we 
determined the effect of ATN-161 on CD45, a pan leukocyte marker, at PSD3 via 
immunofluorescence. Again, fewer infiltrating cells were found in the ipsilateral 
stroked brain parenchyma with ATN-161 treatment (Figure 4.9C and Figure 4.9D; 
p=0.0225; Vehicle 499674±109793, n=7; ATN-161 215451±37499, n=8). Taken 
together, inhibition of integrin α5β1 with ATN-161 reduces the inflammatory load 
following ischemic stroke.  
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Discussion 
Our goal was to determine the therapeutic potential of blocking the α5β1 integrin 
with ATN-161 in experimental ischemic stroke. ATN-161 has been previously 
described as an anti-angiogenic therapeutic, where the safety and efficacy of ATN-
161 have been described in cancer pre-clinical research and clinical trials (159). 
Here, we demonstrated that ATN-161 treatment led to decreases in infarct volume, 
edema, and functional deficit through inhibition of the integrin α5β1 following 
experimental ischemic stroke. Furthermore, we found that post-stroke ATN-161 
administration stabilizes the BBB as evidenced by decreased IgG extravasation, 
stabilization of collagen IV and claudin-5 expression, as well as significantly fewer 
infiltrated leukocytes, and decreases in both MMP-9, CXCL12, and IL-1β	mRNA 
expression. These results are consistent with our previous studies using 
endothelial selective α5KO	 mice that demonstrated that these mice were 
profoundly resistant to ischemic injury and BBB disruption (65). To our knowledge, 
the current study is the first to demonstrate therapeutic efficacy of inhibiting integrin 
α5β1 in ischemic stroke. 
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Importantly, ATN-161-mediated effects on function only occurred after all three 
injections were administered. This suggests a need for continuous acute and 
subacute inhibition of integrin α5β1  following ischemic stroke to inhibit any 
intermittent vascular remodeling that may occur. “Flooding the system” with ATN-
161 is possible as previous clinical trials (Phase I and II for tumorigenesis) showed 
limited side effects (dry mouth, cellulitis, and paresthesia at 1 mg/kg 10-minute 
infusions for one out of four patients) (156,159,278). Our findings further support 
the reported safety of ATN-161 with our treated mice exhibiting no physiological 
differences (Figure 4.2) compared to their controls. ATN-161 has been shown to 
bind not only integrin α5β1, but also integrins αvβ3 and α6β1, though preference 
is for integrin α5β1 when highly expressed )156). Furthermore, integrin αvβ3 and 
α6β1 expression after stroke is more acute and very brief, potentially limiting the 
non-specificity of ATN-161 (279). 
 
In this study, we used only one dosage of ATN-161 (1mg/kg via IP injection) based 
on previous research by Donate et al. which showed that ATN-161 exhibits a U-
shaped dose response curve in vitro, where doses equivalent to 1-5 mg/kg 
produced the most significant reduction in activity (angiogenesis and tumor growth), 
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with 1 mg/kg being the most effective (156). Therefore, additional stroke dose-
response studies should be performed. Likewise, additional studies addressing 
ATN-161’s therapeutic window, and potential long-term effects, need to be 
conducted.  
 
Upon ATN-161 administration, we found less IgG extravasation in the brain 
parenchyma, in agreement with our results in stroked α5 KO mice that also 
exhibited little/no post-stroke IgG extravasation. The decreased IgG extravasation 
is indicative of reduced BBB permeability as normal paracellular transport allows 
free passage of 80 Da proteins, while IgG is size limited at 150 kDa (16,279-280). 
BBB stability, especially TJ integrity, is severely compromised following ischemic 
stroke (281). Osada et al implicated β1-integrins as major regulators of tight 
junction expression and BBB permeability, particularly claudin-5 (70). Further 
analyses showed a significant increase in claudin-5 (tight junction) and collagen IV 
(ECM) protein, while ECM degradation protein, MMP-9, decreased. Inhibition of 
integrin α5β1 via ATN-161 also resulted in reduced IL-1β expression and fewer 
infiltrating CD45+ leukocytes. Leukocytes (neutrophils, monocytes, macrophages, 
etc.) are highly implicated in increasing edema through adhesion of β2 integrin 
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(282-285). However, under inflammatory conditions, neutrophils show increased 
expression of integrin α5β1 located in intracellular vesicles and promote neutrophil 
migration through recycling (201,259,285-286). Furthermore, decreased integrin 
α5β1 levels have been shown to reduce monocytic binding as well as decreased 
IL-1β and MMP-9 expression on leukocytes (201,284,287). Decreased leukocytic 
MMP-9s are associated with reduced BBB leakage, reduced collagen IV 
proteolysis, decreased neutrophil infiltration, and a relative absence of 
hemorrhagic transformation (288). Additionally, we observed conservation of 
CXCL12 transcription post-stroke with ATN-161 administration. The chemokine, 
CXCL12, has been shown to be protective in hypoxia pre-conditioning by 
anchoring astrocytic endfeet to BBB proteins, thus reducing leukocytic infiltration 
and increased BBB permeability (277). Our results suggest that integrin α5β1 may 
play a significant role in regulating claudin-5 expression in endothelial cells, while 
also regulating neutrophilic infiltration and the associated mechanisms of BBB 
breakdown (such as IL-1β and CXCL12 transcription and collagen IV proteolysis). 
 
As integrin α5β1  is pro-angiogenic, long-term inhibition may prove to be 
deleterious as previous studies have shown that patients with increased vascular 
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density tend to have better stroke outcomes (152,280,289). Furthermore, studies 
using angiogenic promotors, particularly VEGF, resulted in increased, leaky 
vessels with no impact on infarct volume when induced post-stroke (152,272). 
Collectively, this confirms that timing is everything regarding post-stroke 
angiogenesis. As vascular remodeling and pruning involves disassembly of brain 
vessels, it leaves those vessels vulnerable to the influx of inflammatory cells, 
cytokines, and reactive oxygen species, which are all known to exacerbate 
damage. Thus, early inhibition of endothelial cell activation / angiogenesis via ATN-
161 may be beneficial in prohibiting the inflammatory cascade and BBB breakdown, 
while the short half-life (3-4.5 hours) could allow for future angiogenesis to proceed 
(159). This may also allow for the intriguing possibility of combining early / acute 
inhibition of α5β1 integrin with its later activation to collectively limit early injury and 
subsequently promote angiogenic neurorepair.  
 
Intriguingly, our results are seemingly in direct contrast to a recent study 
demonstrating that administration of a single IP dose of the small peptide α5β1 
integrin agonist PHSRN, 24 hours after rat transient MCAO was both 
neuroprotective, proangiogenic and increased neurogenesis (290). In their study, 
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they noted that PHSRN increased α5 integrin expression on PSD3 (in contrast we 
noted that ATN-161 decreased α5 integrin on PSD3), and activated several known 
downstream signaling agents of α5β1 including pFAK, p-C-Raf, Ras, pERK, and 
VEGF, the latter of which was speculated to be the primary mechanism of 
therapeutic benefit. Furthermore, they did not examine any aspects of the BBB, 
edema, or inflammation, but rather speculated that initiating treatment 24 hours 
after stroke would alleviate potential deleterious effects of upregulated VEGF on 
the BBB.  
 
These seemingly contrasting results may be reconciled by pointing out several 
differences between the two studies. Besides the obvious differences (rat versus 
mouse transient MCAO model, single versus repeated dosing, etc.), ATN-161 is 
known to preferentially target and interact with the activated form of α5β1 integrin, 
i.e. that which is present in the brain after stroke, while PHSRN shows no 
predilection for any particular α5β1 integrin state (156). Therefore, it cannot be 
ruled out that some, or even a significant extent of PHSRN’s post-stroke effects 
seen by Wu et al could be due to off-target non-cerebral α5β1 or integrin αvβ3 
(179) integrin interactions. Indeed, Wu et al hint at a potential PHSRN interaction 
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in the liver as a confounding factor, but failed to show any systemic effects after 
PHSRN administration. A therapeutic benefit of agonizing, or enhancing, α5β1 
integrin after stroke is also inconsistent with our findings that α5β1 integrin 
endothelial-cell specific KO mice are profoundly resistant to ischemic brain injury 
(65). Finally, previous studies have shown PHSRN to have inhibitory effects on 
integrin binding to fibronectin as both the synergy region (PHSRN) and RGD are 
necessary (291). In any event, an emerging body of evidence appears to indicate 
that modulating (activating or inhibiting) α5β1 integrin after ischemic stroke could 
be therapeutic. 
 
Limitations of our study include the fact that our transient MCA occlusion model 
produces reproducible, but small and cortically limited infarcts which could 
minimize ATN-161’s therapeutic effects (stroke volumes cannot be determined as 
smaller than zero). Furthermore, these small infarcts show limited motor and 
sensory effects, thus hampering our ability to test behavioral deficits past the 
maximum expansion at PSD3. Therefore, follow-up studies should include 
additional stroke models as well as the study of aged, female and co-morbid 
animals as per the STAIR recommendations (267).   
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Conclusion 
Our studies show that inhibition of α5β1  integrin with ATN-161 is beneficial 
following experimental ischemic stroke through reduction of infarct volume and 
edema, while also transiently increasing functional outcomes. Furthermore, ATN-
161 stabilizes the BBB, and reduces inflammation / immune cell infiltration into the 
brain. Collectively, our results suggest that ATN-161 may be a promising, novel 
therapeutic for ischemic stroke. 
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Chapter 5: Discussion 
In this chapter, I will briefly overview results from Chapters 2 and 4. Next, I will 
address limitations of the studies discussed above. Next, I will address the 
potential mechanism of action we believe integrin a5b1 works through following 
ischemic stroke. Finally, I will address limitations of the current studies, and 
present future directions. 
 
Summary 
Current therapies for ischemic stroke, t-PA and endovascular thrombectomy, are 
focused on removal of the thrombus, but do not address increased inflammation, 
BBB dysfunction, or any other pathologic mechanism after reperfusion. In 
particular, increased infarct volume and worsened patient outcomes have been 
implicated with decreased BBB dysfunction (16). Using the first line of BBB 
defense, endothelial cells, endothelial integrins, particularly the family of b1 
integrins, have been implicated in TJ expression and neurovascular remodeling 
(70, 292). Previously in our lab, absence of the b1 integrin a5b1 in endothelial cells 
is neuroprotective against ischemic stroke. This was attributed to conservation of 
claudin-5, leading to a stabilized post-stroke BBB as determined by IgG staining 
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(165). Following experimental ischemic stroke, we therefore formed two 
hypotheses: 1) inhibition of integrin a5b1 would result in smaller infarct volumes 
and better outcomes and 2) the BBB would be less permeable with less active 
integrin a5b1.  
 
Before we moved toward therapeutic inhibition, we wanted to determine if integrin 
a5b1 was acutely upregulated in our stroke model. We found an increase in 
integrin a5b1 beginning at PSD2 with expression continually increasing to PSD4. 
These results are similar to other reported experimental stroke and hypoxia models, 
as discussed in Chapter 2. Next, we determined if the upregulated integrin a5b1 
was accessible to administered therapeutics, a common issue when targeting the 
cerebrum. This is vital when introducing compounds that target the brain. The BBB 
prevents free movement of molecules larger than 80 Da, thus limiting most 
therapeutics that need to reach the brain parenchyma (226). Intriguingly, integrin 
a5b1 vascular localization was observed to be region dependent. When looking in 
the peri-infarct, integrin a5b1 appears to be located in the vascular lumen, while 
expression in the core shifted to the abluminal compartment at PSD3.  It is 
important to distinguish that our model does not reach full evolution of the stroke 
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(i.e. the largest the stroke will become) until PSD3. Thus, these collective results 
suggest the expression of integrin a5b1 in the non-damaged tissue (peri-infarct) is 
a good indicator of integrin a5b1 immediately upon reperfusion. However, further 
investigation at reperfusion, PSD1 and PSD2 would provide insight into the 
movement of integrin a5b1 as its’ expression increases.  
 
Lastly, the vessels in the peri-infarct failed to show fibronectin, fibrinogen or Ab 
binding (co-localization) to integrin a5b1. This, in addition to the varying 
localization of integrin a5b1, suggests a potential new role of integrin a5b1 
following reperfusion. Because of the divergent vascular presentation of integrin 
a5b1, a couple of mechanisms could be used to explain the purpose for this 
movement. One possibility is the activation of integrin a5b1 by reperfusion 
mechanisms (HIF-1a, ATP depletion, etc.) and use transendothelial migration to 
travel from the apical to basal endothelium for basement membrane fibronectin 
binding. Interestingly, integrin a5b1 has been found in caveolin-1 intracellular 
vesicles, implicating this possibility (293). Another potential hypothesis is the 
participation of integrin a5b1 in the inflammatory cascade. Specifically, leukocyte 
migration to the area of damage and infiltration into the parenchyma. Currently, 
  4 
evidence points to integrin a5b1 having an inflammatory role (discussed in more 
detail below), but investigation into transendothelial migration still needs to be 
determined.  
 
Once we determined the potential of therapeutic targeting of integrin a5b1 in our 
experimental stroke model, we tested our first hypothesis on the effectiveness of 
the small peptide ATN-161 in experimental ischemic stroke. This integrin a5b1 
inhibitor we selected is an FDA-approved small peptide, ATN-161. ATN-161 
targets the PHSRN, or synergy region, of integrin a5b1, which increases the 
binding affinity of integrin a5b1 for fibronectin over other RGD binding integrins 
(integrin avb3, a6b1, etc.).  ATN-161 is reported to have an inverted U-dose 
therapeutic curve, where doses of 1 mg/kg - 5 mg/kg (particularly the 1 mg/kg 
dose) are the most effective in preventing integrin a5b1 mediated angiogenesis 
(156).  
 
Additionally, ATN-161 has been used in solid tumor clinical trials. Though no 
significant benefit was determined, ATN-161 is proven to be safe. When 
administered by IV infusions over a two-week period, the most serious side effects 
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reported were paresthesia, nausea, sweating (159). Ischemic stroke is a different 
model with different pathophysiology, we needed to determine the safety of ATN-
161 before further steps could be taken. After the first dose of IP injected, 1 mg/kg 
ATN-161, we detected no significant changes in animal weight, heart rate, pulse 
distension (comparable to blood pressure), or body temperature when compared 
to Vehicle treated controls.  Lastly, when observed over three days, no significant 
change in weight was reported.  
 
In addition to determining the dose, we performed many trials to determine the 
dosing frequency of ATN-161. Initially, we used the expression of integrin a5b1 
and the irreversible binding of ATN-161 (156) as a guide. Thus, we hypothesized 
that PSD1 administration of ATN-161 would be sufficient to prevent the increase 
observed at PSD2. However, multiple experiments showed inconsistent benefit (i.e. 
some mice showed infarct volumes comparable to vehicle treated mice, while 
others showed ~90% reduction) (Figure 5.1A). We hypothesized that we missed 
the early upregulation of integrin a5b1 in some of the animals. Next, we attempted 
ATN-161 administration immediately after reperfusion and on PSD1. Again, we 
saw no benefit with the two-dose structure (Figure 5.1B). We suspected this may 






Figure 5.1: Infarct volume for variable ATN-161 dosing. Infarct analysis of TTC 
stains from IP injection on A). PSD1 only and B). IP immediately following 
reperfusion and PSD1.   
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 be attributed to the inability of ATN-161 to completely prevent the strong 
upregulation of integrin a5b1 from PSD2 to PSD4 because of ATN-161’s short 
half-life (3.5-5 hours). Finally, we used a three-dose administration strategy where 
ATN-161 was administered immediately at reperfusion, PSD1, and PSD2. This 
dosing paradigm resulted in data that was consistent and effective. 
 
We moved forward using the three-dose paradigm of ATN-161 at 1 mg/kg and 
found that mice treated with ATN-161 experienced significantly reduced infarct 
volumes (by ~50%) in both TTC images and the clinically relevant T2-weighted 
MRI when compared to Vehicle treated controls. Cerebral edema was also 
reduced on ADC MRI scans, a major cause of mortality following ischemic stroke 
(11). To determine the extent of functional recovery, we used a novel 11-point 
Neuroscore that was developed in our laboratory and is based off the clinically 
applied modified Rankin Score. ATN-161 administration revealed a decrease in 
dysfunction (lower numbers on the Neuroscore) at PSD3.  Intriguingly, when we 
compared the Neuroscore results at baseline, PSD1, and PSD3, we found 
statistical improvement only at PSD3 following all three injections of ATN-161. This, 
in addition to the inconsistent infarct volume results with a one dose and two dose 
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administrations, implies a therapeutic effect where all three injections are required 
to effectively inhibit the upregulation of integrin a5b1. 
 
With our first hypothesis proven correct, we then moved to our second hypothesis: 
post-stroke BBB permeability is reduced following ATN-161 administration. First, 
we determined the extent of BBB dysfunction using the presence of IgG, a 150kDa 
protein, in the brain parenchyma of perfused tissue. IgG detection is a commonly 
used approach to assay BBB permeability in vivo as it is too large to pass through 
the BBB under normal circumstances, but will be found in cerebral parenchyma 
upon BBB disruption. Consistent with our discovery in a5 KO mice (65), ATN-161 
treated mice showed a significant reduction in BBB permeability (less IgG in 
cerebral parenchyma) when compared to the Vehicle treated controls. Next, we 
wanted to further examine the endothelial and basement membrane stability by 
looking at additional cerebrovascular elements related to stability. We found ATN-
161 treated mice expressed similar levels of the basement membrane protein 
collagen IV, and extracellular matrix proteinase MMP-9, as compared to sham 
mice. Vehicle treated mice, on the other hand, showed significant increases in 
MMP-9 and decreased collagen IV, suggesting a dysfunctional basement 
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membrane, all of which is absent in ATN-161 treated mice. Furthermore, ATN-161 
stabilized the TJ protein, claudin-5 in the ischemic core as compared to Vehicle 
treated mice. Increased claudin-5 is associated with less paracellular permeability, 
though function of claudin-5 (extracellular localization and tyrosine 
phosphorylation) has not been determined following ATN-161. Collectively, these 
results show that ATN-161 treated mice have stable cerebrovascular structures 
and thus, a less permeable BBB following experimental ischemic stroke.  
 
Furthermore, it is also important to note that the extent of BBB permeability is not 
only due to cerebrovascular stability and TJ expression/function, but it is also due 
to the increase in inflammation. As described in Chapter 3, infiltrating leukocytes 
occur during occlusion and continue long after reperfusion, exacerbating the space 
between endothelial cells, edema (swelling), and expansion of brain damage. 
Previous studies have shown the inability of integrin a5b1 inhibited leukocytes to 
migrate, highlighting a potential role in post-stroke pathophysiology (261-262). We 
used a pan-leukocyte marker, CD45+, on perfused tissue, and unsurprisingly 
found ATN-161 administration resulted in reduced CD45+ cells when compared to 
Vehicle controls. Because of saline perfusion, the amount of recruiting and rolling 
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leukocytes are limited. Next, we determined a decrease in the transcription of the 
IL-1b cytokine. We attributed this to an indirect product of reduced infiltration 
because leukocytes are known to release a number of factors, including cytokines 
and the earlier mentioned MMP-9. This introduced a conundrum, 1) was the 
reduced infiltration of leukocytes due to reduced BBB permeability, 2) was ATN-
161 directly inhibiting leukocytic a5b1 and preventing migration, thus reducing 
BBB dysfunction, or 3) a combination of both possibilities.   
 
Thus, we next investigated the ability of leukocytes to be recruited to the site of 
injury through the broad leukocyte recruiting chemokine, CXCL12. The presence 
of CXCL12 is proven to reduce leukocytic infiltration following chronic hypoxia and 
inflammatory autoimmune disease (277).  As all experiments leading to this point 
suggest a role for activate integrin a5b1 in promoting leukocytic infiltration, we 
unsurprisingly found increased CXCL12 transcription under ATN-161 treatment.  
 
Collectively, we found the inhibition of integrin a5b1 via ATN-161 following 
experimental ischemic stroke reduced dysfunction and infarct volumes through 
reduction of BBB permeability with interference in two different mechanisms, 
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inflammation and tight junction protein expression. Thus, ATN-161 could be a new 
therapeutic treatment for those experiencing reperfusion following experimental 
stroke. Furthermore, these results show a post-stroke inflammatory and BBB 
function role mediated by integrin a5b1. These are summarized in Figure 5.2. 
 
Experimental caveats and limitations 
The distal transient occlusion model used in all experiments, tandem/transient 
CCA/MCA occlusion model, is a clinically relevant experimental model exhibiting 
limited mortality (~5% in our laboratory, 65). The injury involves occluding the M2 
branch of the MCA, resulting in an injury limited to the cortex. All animals 
undergoing this surgery were exposed to similar amounts of anesthesia, 
experimental procedure, occlusion period, and recovery time. Even with the 
benefits of the model, there are still some caveats that need to be addressed. Most 
notably, though all animals are genetically identical, differences in collateral 
vasculature, the surrounding, supporting vasculature, can vary greatly. Clinically, 
plasticity and damage has been associated with increased vasculature (294-295). 
Thus, in a pre-clinical setting, the mouse cerebrovasculature could affect stroke 
size and variance, independent of the model and treatment.  





Figure 5.2: A visual overview of integrin a5b1’s mechanism following experimental 
stroke.   
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We also focused on a limited time point, PSD3, when determining efficacy of ATN-
161 treatment as well as integrin a5b1 localization. As previously mentioned, the 
PSD3 time point in our model represents the point of complete resolution of the 
core into the peri-infarct. Thus, by analyzing our outcomes at PSD3, we ultimately 
determined the ability of ATN-161 to prevent the expansion of the core into the 
peri-infarct region, reminiscent of human ischemic stroke. However, this acute time 
point misses the effect on delayed mechanisms, particularly angiogenesis, as 
integrin a5b1 is the main promoter.  This will be discussed in further detail in the 
future directions section below. 
 
In addition to the resulting stroke volume, our surgical outcomes affect the 
behavioral performance and tests chosen. Because these are small, cortical 
infarcts, mice will generally experience rear limb weakness and loss of sensation, 
though fore paw and ocular involvement can occur. The 11-point Neuroscore exam 
is more sensitive than other available behavioral tests such as open field and 
rotarod, although the sensitivity is not enough to overcome the small cerebral injury, 
introducing an unanticipated ceiling effect evident by a return to sham functional 
levels on PSD7 and PSD14.  
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The therapeutic we chose to inhibit integrin a5b1 was the small peptide, ATN-161. 
Though it is advertised as a specific integrin a5b1 inhibitor, some binding to 
integrin avb3 and a6b1 has been reported (156). Though potentially significant, 
we determined not to pursue the potential effects of inhibition of these other 
integrins in addition to integrin a5b1, as their expression is limited after stroke as 
compared to integrin a5b1 (see Chapter 1 for more details). Furthermore, the more 
chronically elevated integrin avb3 has been shown to increase integrin a5b1’s 
affinity to fibronectin through cross-talk. Thus, inhibition of both a5b1 and avb3 
integrins may ultimately be beneficial in increasing the efficacy of ATN-161 in 
ischemic stroke.  
 
With the addition of repeated dosing, we encountered a new limitation of our model. 
Because of the vascular nature of integrin a5b1, we initially used the vascular 
approach for ATN-161 administration through IV injections. Because integrin a5b1 
is located luminally and in direct contact with the blood and IV drug administrations 
are the most commonly used in the clinic. IV injections in mice are generally given 
using the tail vein. Repeated injections, especially over consecutive days cause 
scarring and deterioration of the tails, reducing the success of subsequent IV 
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injections. In fact, successful injections were reduced to 20% from PSD1 to PSD2, 
resulting in exclusion of mice. Though the three dose animals experienced ATN-
161 efficacy, the exceptionally low animal numbers were expensive and 
statistically limiting. In fact, experiments were required to be high powered to 
achieve a minimum of n=3 per treatment group. Thus, we turned our attention to 
another mode of injection, IP, to reduce animal experimental loss while still 
receiving benefit. Though, IP injections are less direct and result in delayed 
vascular uptake from the abdomen (297), they are eventually absorbed by 
surrounding vasculature. This potentially reduces the amount of drug entering the 
vasculature, thus reducing the concentration in blood. Importantly, IP 
administration of ATN-161 was successful, and mice still experienced benefits, 
though not to the significance of IV injections. 
 
Future Directions 
Collectively, our results indicate that ATN-161 is safe and effective in treating 
ischemic stroke in a clinically relevant dosing paradigm and experimental model. 
However, it would be irresponsible to ignore the collective failures of clinical trials 
for ischemic stroke, none the less the disappointment of ATN-161 in cancer clinical 
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trials. Thus, future experiments are needed to further investigate the role of integrin 
a5b1 and ATN-161 in ischemic stroke before an attempt at clinical translation is 
pursued.  
 
Though our previous results suggest an endothelial integrin a5b1 dominant 
pathway (in Tie2Cre a5 KO mice), our results in Chapter 4 indicate a role for 
integrin a5b1 in the post-stroke inflammatory cascade. This is further supported 
by previous research on integrin a5b1’s role in cell migration under flow conditions 
(reviewed in Chapter 3). Thus, we need to determine the effect of inflammation 
under integrin a5b1 control on a cellular level through the effect of ATN-161 on 
migrating cells. To test this, we will initially isolate leukocytes from bone marrow 
from mice for culture. As described previously, we will administer ATN-161 
following either oxygen-glucose deprivation or TNF-a administration to test both 
conditions found following reperfusion in ischemic stroke. Based on the literature, 
we expect ATN-161 treated cells to exhibit less migration than their control cells.  
 
Another potential avenue is to ablate infiltrating neutrophils (the first infiltrating cells 
as discussed in Chapter 3) using a Ly6G antibody prior to experimental ischemic. 
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The Ly6G antibody has been shown to prohibit neutrophil production 2-3 days 
following injection (298-299). This time frame is consistent with the resolution of 
our model, thus allowing us to study the effects of endothelial integrin a5b1 
independently. The observed strokes will be smaller, but we will be able to observe 
the effects of inflammation and BBB permeability following ATN-161 administration 
in the same dosing paradigm discussed in Chapter 4. Following neutrophil ablation 
and ATN-161 administration, we hypothesize that endothelial integrin a5b1 is the 
main promoter of BBB permeability independent of inflammation, so claudin-5, 
MMP-9 and collagen IV will be unaffected. Furthermore, we can observe leukocyte 
migration in a5 KO mice using the CD45+ antibody in perfused (infiltrating cells) 
and non-perfused (leukocytic rolling) tissue to determine if endothelial integrin 
a5b1 are responsible for leukocyte infiltration.  
 
Though our previous results suggest an endothelial integrin a5b1 dominant 
pathway (in Tie2Cre a5 KO mice), our results in Chapter 4 indicate a role for 
integrin a5b1 in the post-stroke inflammatory cascade. This is further supported 
by previous research on integrin a5b1’s role in cell migration under flow conditions 
(reviewed in Chapter 3). Thus, we need to determine the effect of inflammation 
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under integrin a5b1 control on a cellular level through the effect of ATN-161 on 
migrating cells. To test this, we will initially isolate leukocytes from bone marrow 
from mice for culture. As described previously, we will administer ATN-161 
following either oxygen-glucose deprivation or TNF-a administration to test both 
conditions found following reperfusion in ischemic stroke. Based on the literature, 
we expect ATN-161 treated cells to exhibit less migration than their control cells.  
 
Next, we need to determine the mechanism of action for clauidn-5 using several in 
vitro experiments. Though the exact mechanism through which integrin a5b1 and 
claudin-5 expression are tied has not yet been determined, there are two 
possibilities.  The first, as shown in Figure 5.2, shows fibronectin bound integrin 
a5b1 inhibiting PKA, a protein kinase, and GDI, a GDP inhibitor regulating Rho 
GTPases. As a result, cytoskeleton regulators, RhoA and ROCK1,  are increased, 
promoting phosphorylation and inactivation of claudin-5 (as described in our NIH 
RO1). While this may apply, current results show a decrease in claudin-5 
transcription (Chapter 4) and inability of integrin a5b1 to bind fibronectin following 
stroke (Chapter 2). Another possibility is activation of integrin a5b1 acting as an 
inhibitor of the canonical Wnt/b-cat pathway (Figure 5.4). This pathway seems 
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more likely, because we see a loss in transcription of claudin-5. Here, activated 
integrin a5b1 acts as an inhibitor of the canonical Wnt/b-cat pathway. Upon 
inhibition, b-catenin is decreased and does not translocate to the nucleus, 
preventing transcription of target genes, such as claudin-5.  
 
To test both pathways, we are currently using cultured brain endothelial cells to 
test for the cell signaling pathway upon activation following oxygen-glucose 
deprivation (OGD, also referred to as “stroke in a dish”) and after an inflammatory 
state (i.e. adding the inflammatory cytokines TNF-a or IL-1b). Following ATN-161 
administration and/or inhibitors based on the pathways in Figure 5.4 and 5.5, we 
plan to quantify qPCR, western blot, and immunoprecipitation.   
 
In Chapter 4, we focused only on the effects of removal of integrin a5b1 activity 
via ATN-161. It is important to note that ATN-161, though advertised as an inhibitor 
of integrin a5b1, also possesses some specificity for integrin avb3 and a6b1 (296). 
As discussed earlier in this chapter, both integrin a6b1 and avb3 are unlikely 
targets, however the full extent of their role in ischemic stroke has not been 
determined. A few additional experiments need to be performed to determine the  
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Figure 5.3: Representative diagram of integrin a5b1 working through PKA and 
ROCK1 to inactivate claudin-5 with phosphorylation. 
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Figure 5.4: Representative diagram of integrin a5b1 working through the 
canonical Wnt pathway to prevent claudin-5 translocation. 
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specificity of ATN-161. First, we can determine binding of ATN-161 using 
biotinylation techniques and co-label with integrins a5b1, avb3, and a6b1. 
 
Previous studies with ATN-453, a biotinylated version of ATN-161 that is no longer 
available, have shown a high preference for integrin a5b1 binding over avb3 and 
a6b1 when integrin a5b1 is expressed at high levels (156). As this is similar to 
what is seen in ischemic stroke, we do not expect to see different results.  
 
In addition to the specificity of ATN-161, investigation into chronic mechanisms, 
such as angiogenesis, has not yet been determined. Angiogenesis is a delayed 
process, where new vessels are not seen until PSD3 and continually increase 
through PSD14. However, the initiation of cerebrovascular remodeling is observed 
within hours following reperfusion (292). Mainly, the role of angiogenesis is to 
restore circulation to areas of damage from ischemia, as well as to support other 
aspects of neurorepair (i.e. neurogenesis) and are viewed as a high priority for 
post stroke recovery (300).  As a main promoter, acute inhibition of integrin a5b1 
may also negatively impact plasticity and neurorestoration. We hypothesize that 
the process of angiogenesis is largely not impacted, though delayed. Additionally, 
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because there is less damage with integrin a5b1 inhibition, there is also less repair 
that needs to occur. Thus, even if delayed, angiogenesis process will be less 
essential for repair following the stroke. Integrin a5b1 expression continually 
increases through PSD7 before decreasing upon angiogenesis at PSD14. This, 
combined with the short half-life of ATN-161 and the short period of administration 
(up to 48 hours post-stroke), suggests a reduction in acute cerebrovascular 
remodeling, but left with the capabilities for chronic remodeling. Additional support 
for this theory is shown by no difference in function on PSD14 in ATN-161 treated 
mice compared to controls (Figure 5.5).   
 
Finally, it appears that integrin a5b1 may have a more diverse role in different 
diseases. Increases in integrin a5b1 have been observed in animal models of 
Moya Moya (301) and vascular dementia. Both diseases are a result of faulty 
cerebrovasculature and angiogenesis. Thus, there are current investigations into 
administrating ATN-161 prior to disease onset. 
 







Figure 5.5: 11-point Neuroscore from baseline to PSD14.  
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Conclusion  
Though integrin a5b1 has been historically studied as a pro-angiogenic endothelial 
integrin. In this discussion, we described the effects of integrin a5b1 on post-stroke 
inflammation and cerebrovascular stability following ischemic stroke. With the 
administration of the small peptide, ATN-161, these results are reversed,  
decreasing infarct volumes and improving outcomes. Thus, investigation into 
targeting integrin a5b1 with ATN-161 in the clinical treatment of ischemic stroke 
merits additional investigation. 
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